<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2d1 20170631//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="article" dtd-version="1.2d1" specific-use="production" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MEDRXIV</journal-id>
<journal-title-group>
<journal-title>medRxiv</journal-title>
<abbrev-journal-title abbrev-type="publisher">medRxiv</abbrev-journal-title>
</journal-title-group>
<publisher>
<publisher-name>Cold Spring Harbor Laboratory</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1101/2020.07.14.20152728</article-id>
<article-version>1.2</article-version>
<article-categories>
<subj-group subj-group-type="hwp-journal-coll">
<subject>Infectious Diseases (except HIV/AIDS)</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of aggregate data from randomised controlled trials</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Jolliffe</surname><given-names>David A</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">&#x2020;</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5071-7654</contrib-id>
<name><surname>Camargo</surname><given-names>Carlos A</given-names>
<suffix>Jr</suffix>
</name>
<xref ref-type="aff" rid="a3">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sluyter</surname><given-names>John D</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Aglipay</surname><given-names>Mary</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Aloia</surname><given-names>John F</given-names></name>
<xref ref-type="aff" rid="a6">6</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ganmaa</surname><given-names>Davaasambuu</given-names></name>
<xref ref-type="aff" rid="a7">7</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bergman</surname><given-names>Peter</given-names></name>
<xref ref-type="aff" rid="a8">8</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Borzutzky</surname><given-names>Arturo</given-names></name>
<xref ref-type="aff" rid="a9">9</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Damsgaard</surname><given-names>Camilla T</given-names></name>
<xref ref-type="aff" rid="a10">10</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dubnov-Raz</surname><given-names>Gal</given-names></name>
<xref ref-type="aff" rid="a11">11</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Esposito</surname><given-names>Susanna</given-names></name>
<xref ref-type="aff" rid="a12">12</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gilham</surname><given-names>Clare</given-names></name>
<xref ref-type="aff" rid="a13">13</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Ginde</surname><given-names>Adit A</given-names></name>
<xref ref-type="aff" rid="a14">14</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Golan-Tripto</surname><given-names>Inbal</given-names></name>
<xref ref-type="aff" rid="a15">15</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Goodall</surname><given-names>Emma C</given-names></name>
<xref ref-type="aff" rid="a16">16</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Grant</surname><given-names>Cameron C</given-names></name>
<xref ref-type="aff" rid="a17">17</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Griffiths</surname><given-names>Christopher J</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hibbs</surname><given-names>Anna Maria</given-names></name>
<xref ref-type="aff" rid="a18">18</xref>
<xref ref-type="aff" rid="a19">19</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Janssens</surname><given-names>Wim</given-names></name>
<xref ref-type="aff" rid="a20">20</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Khadilkar</surname><given-names>Anuradha Vaman</given-names></name>
<xref ref-type="aff" rid="a21">21</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Laaksi</surname><given-names>Ilkka</given-names></name>
<xref ref-type="aff" rid="a22">22</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Lee</surname><given-names>Margaret T</given-names></name>
<xref ref-type="aff" rid="a23">23</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Loeb</surname><given-names>Mark</given-names></name>
<xref ref-type="aff" rid="a24">24</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Maguire</surname><given-names>Jonathon L</given-names></name>
<xref ref-type="aff" rid="a5">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Majak</surname><given-names>Pawe&#x0142;</given-names></name>
<xref ref-type="aff" rid="a25">25</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mauger</surname><given-names>David T</given-names></name>
<xref ref-type="aff" rid="a26">26</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Manaseki-Holland</surname><given-names>Semira</given-names></name>
<xref ref-type="aff" rid="a27">27</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Murdoch</surname><given-names>David R</given-names></name>
<xref ref-type="aff" rid="a28">28</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Nakashima</surname><given-names>Akio</given-names></name>
<xref ref-type="aff" rid="a29">29</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Neale</surname><given-names>Rachel E</given-names></name>
<xref ref-type="aff" rid="a30">30</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Pham</surname><given-names>Hai</given-names></name>
<xref ref-type="aff" rid="a30">30</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rake</surname><given-names>Christine</given-names></name>
<xref ref-type="aff" rid="a13">13</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rees</surname><given-names>Judy R</given-names></name>
<xref ref-type="aff" rid="a31">31</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rosendahl</surname><given-names>Jenni</given-names></name>
<xref ref-type="aff" rid="a32">32</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Scragg</surname><given-names>Robert</given-names></name>
<xref ref-type="aff" rid="a4">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shah</surname><given-names>Dheeraj</given-names></name>
<xref ref-type="aff" rid="a33">33</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Shimizu</surname><given-names>Yoshiki</given-names></name>
<xref ref-type="aff" rid="a34">34</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Simpson-Yap</surname><given-names>Steve</given-names></name>
<xref ref-type="aff" rid="a35">35</xref>
<xref ref-type="aff" rid="a36">36</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kumar</surname><given-names>Geeta Trilok</given-names></name>
<xref ref-type="aff" rid="a37">37</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Urashima</surname><given-names>Mitsuyoshi</given-names></name>
<xref ref-type="aff" rid="a29">29</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5387-1721</contrib-id>
<name><surname>Martineau</surname><given-names>Adrian R</given-names></name>
<xref ref-type="aff" rid="a1">1</xref>
<xref ref-type="aff" rid="a2">2</xref>
<xref ref-type="corresp" rid="cor1">&#x2020;</xref>
</contrib>
<aff id="a1"><label>1</label><institution>Institute for Population Health Sciences, Barts and The London School of Medicine and Dentistry, Queen Mary University of London</institution>, London, <country>UK</country></aff>
<aff id="a2"><label>2</label><institution>Asthma UK Centre for Applied Research, Queen Mary University of London</institution>, London, <country>UK</country></aff>
<aff id="a3"><label>3</label><institution>Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a4"><label>4</label><institution>School of Population Health, University of Auckland</institution>, Auckland, <country>New Zealand</country></aff>
<aff id="a5"><label>5</label><institution>Department of Pediatrics, St Michael&#x2019;s Hospital</institution>, Toronto, Ontario, <country>Canada</country></aff>
<aff id="a6"><label>6</label><institution>Bone Mineral Research Center, Winthrop University Hospital</institution>, Mineola, NY, <country>USA</country></aff>
<aff id="a7"><label>7</label><institution>Department of Nutrition, Harvard School of Public Health</institution>, Boston, MA, <country>USA</country></aff>
<aff id="a8"><label>8</label><institution>Department of Laboratory Medicine, Karolinska Institutet</institution>, Stockholm, <country>Sweden</country></aff>
<aff id="a9"><label>9</label><institution>Department of Pediatric Infectious Diseases and Immunology, School of Medicine, Pontificia Universidad Cat&#x00F3;lica de Chile</institution>, Santiago, <country>Chile</country></aff>
<aff id="a10"><label>10</label><institution>Department of Nutrition, Exercise and Sports, University of Copenhagen</institution>, Frederiksberg, <country>Denmark</country></aff>
<aff id="a11"><label>11</label><institution>Exercise, Lifestyle and Nutrition Clinic, Edmond and Lily Safra Children&#x2019;s Hospital</institution>, Tel Hashomer, <country>Israel</country></aff>
<aff id="a12"><label>12</label><institution>Pediatric Clinic, Pietro Barilla Children&#x2019;s Hospital, Department of Medicine and Surgery, University of Parma</institution>, Parma, <country>Italy</country></aff>
<aff id="a13"><label>13</label><institution>Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine</institution>, London, <country>UK</country></aff>
<aff id="a14"><label>14</label><institution>Department of Emergency Medicine, University of Colorado School of Medicine</institution>, Aurora, CO, <country>USA</country></aff>
<aff id="a15"><label>15</label><institution>Saban Pediatric Medical Center, Soroka University Medical Center, Faculty of Health Sciences, Ben-Gurion University</institution>, Beer Sheva, <country>Israel</country></aff>
<aff id="a16"><label>16</label><institution>Department of Health Research Methods, Evidence and Impact, McMaster University</institution>, Hamilton, ON, <country>Canada</country></aff>
<aff id="a17"><label>17</label><institution>Department of Paediatrics: Child &#x0026; Youth Health, Faculty of Medical and Health Sciences, University of Auckland</institution>, Auckland, <country>New Zealand</country></aff>
<aff id="a18"><label>18</label><institution>Department of Pediatrics, Case Western Reserve University School of Medicine</institution>, Cleveland, OH, <country>USA</country></aff>
<aff id="a19"><label>19</label><institution>University Hospitals Rainbow Babies and Children&#x2019;s Hospital</institution>, Cleveland, OH, <country>USA</country></aff>
<aff id="a20"><label>20</label><institution>Universitair ziekenhuis Leuven</institution>, Leuven, <country>Belgium</country></aff>
<aff id="a21"><label>21</label><institution>Hirabai Cowasji Jehangir Medical Research Institute</institution>, Maharashtra, <country>India</country></aff>
<aff id="a22"><label>22</label><institution>Faculty of Medicine and Health Technology, University of Tampere</institution>, Tampere, <country>Finland</country></aff>
<aff id="a23"><label>23</label><institution>Division of Pediatric Hematology/Oncology/Stem Cell Transplantation, Columbia University Medical Center</institution>, New York, NY <country>USA</country></aff>
<aff id="a24"><label>24</label><institution>Department of Pathology and Molecular Medicine, McMaster University</institution>, Hamilton, ON, <country>Canada</country></aff>
<aff id="a25"><label>25</label><institution>Department of Pediatric Pulmonology, Medical University of Lodz</institution>, Lodz, <country>Poland</country></aff>
<aff id="a26"><label>26</label><institution>Department of Statistics, The Pennsylvania State University</institution>, Hershey, PA, <country>USA</country></aff>
<aff id="a27"><label>27</label><institution>Department of Public Health, Epidemiology and Biostatistics, Institute of Applied Health Sciences, College of Medical and Dental Sciences, University of Birmingham</institution>, Birmingham, <country>UK</country></aff>
<aff id="a28"><label>28</label><institution>Department of Pathology, University of Otago</institution>, Christchurch, <country>New Zealand</country></aff>
<aff id="a29"><label>29</label><institution>Jikei University School of Medicine</institution>, Tokyo, <country>Japan</country></aff>
<aff id="a30"><label>30</label><institution>Population Health Department, QIMR Berghofer Medical Research Institute</institution>, Queensland, <country>Australia</country></aff>
<aff id="a31"><label>31</label><institution>Department of Epidemiology, Geisel School of Medicine at Dartmouth</institution>, Lebanon, NH, <country>USA</country></aff>
<aff id="a32"><label>32</label><institution>Children&#x2019;s Hospital, Pediatric Research Centre, University of Helsinki and Helsinki University Hospital</institution>, Helsinki, <country>Finland</country></aff>
<aff id="a33"><label>33</label><institution>Department of Paediatrics, University College of Medical Sciences</institution>, Delhi, <country>India</country></aff>
<aff id="a34"><label>34</label><institution>FANCL Research Institute, FANCL Corporation</institution>, Yokohama, <country>Japan</country></aff>
<aff id="a35"><label>35</label><institution>Neuroepidemiology Unit, Melbourne School of Population &#x0026; Global Health, The University of Melbourne</institution>, Melbourne, VIC, <country>Australia</country></aff>
<aff id="a36"><label>36</label><institution>Menzies Institute for Medical Research, University of Tasmania</institution>, Hobart, TAS, <country>Australia</country></aff>
<aff id="a37"><label>37</label><institution>Institute of Home Economics, University of Delhi</institution>, New Delhi, <country>India</country></aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><label>&#x2020;</label>To whom correspondence should be addressed at the Institute for Population Health Sciences, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 58 Turner St, London E1 2AB, UK, Tel: &#x002B;44 207 882 2551 |Fax: &#x002B;44 207 882 2552 |Email: <email>d.a.jolliffe@qmul.ac.uk</email> or <email>a.martineau@qmul.ac.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<year>2020</year>
</pub-date>
<elocation-id>2020.07.14.20152728</elocation-id>
<history>
<date date-type="received">
<day>14</day>
<month>7</month>
<year>2020</year>
</date>
<date date-type="rev-recd">
<day>24</day>
<month>11</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>11</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>&#x00A9; 2020, Posted by Cold Spring Harbor Laboratory</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p></license>
</permissions>
<self-uri xlink:href="20152728.pdf" content-type="pdf" xlink:role="full-text"/>
<abstract>
<title>Abstract</title>
<sec>
<title>Background</title>
<p>A 2017 meta-analysis of data from 25 randomised controlled trials of vitamin D supplementation for the prevention of acute respiratory infections revealed a protective effect of the intervention. Since then, 20 new RCTs have been completed.</p></sec>
<sec>
<title>Methods</title>
<p>Systematic review and meta-analysis of data from randomised controlled trials (RCTs) of vitamin D for ARI prevention using a random effects model. Pre-specified sub-group analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration or dosing regimen. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and the ClinicalTrials.gov registry from inception to 1st May 2020. Double-blind RCTs of supplementation with vitamin D or calcidiol, of any duration, were eligible if they were approved by a Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration, were obtained from study authors. The study was registered with PROSPERO (no. CRD42020190633).</p></sec>
<sec>
<title>Findings</title>
<p>We identified 45 eligible RCTs (total 73,384 participants). Data were obtained for 46,331 (98.0%) of 47,262 participants in 42 studies, aged 0 to 95 years. For the primary comparison of vitamin D supplementation vs. placebo, the intervention reduced risk of ARI overall (Odds Ratio [OR] 0.91, 95% CI 0.84 to 0.99; P for heterogeneity 0.01). No statistically significant effect of vitamin D was seen for any of the sub-groups defined by baseline 25(OH)D concentration. However, protective effects were seen for trials in which vitamin D was given using a daily dosing regimen (OR 0.75, 95% CI 0.61 to 0.93); at daily dose equivalents of 400-1000 IU (OR 0.70, 95% CI 0.55 to 0.89); and for a duration of &#x2264;12 months (OR 0.82, 95% CI 0.72 to 0.93). No significant interaction was seen between allocation to vitamin D vs. placebo and dose frequency, dose size, or study duration. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0.97, 95% CI 0.86 to 1.09). Risk of bias within individual studies was assessed as being low for all but three trials. A funnel plot showed left-sided asymmetry (P=0.008, Egger&#x2019;s test).</p></sec>
<sec>
<title>Interpretation</title>
<p>Vitamin D supplementation was safe and reduced risk of ARI, despite evidence of significant heterogeneity across trials. Protection was associated with administration of daily doses of 400-1000 IU vitamin D for up to 12 months. The relevance of these findings to COVID-19 is not known and requires investigation.</p></sec>
<sec>
<title>Funding</title>
<p>None</p>
</sec>
<sec>
<title>Research in context</title>
<sec>
<title>Evidence before this study</title>
<p>The active vitamin D metabolite, 1,25-dihydroxyvitamin D, induces innate immune responses to respiratory viruses and bacteria. A previous meta-analysis of individual participant data from 10,933 participants in 25 randomised controlled trials of vitamin D supplementation for the prevention of acute respiratory infection demonstrated an overall protective effect (adjusted Odds Ratio [aOR] 0.88, 95% confidence interval 0.81 to 0.96). Sub-group analysis revealed most benefit in those with the lowest vitamin D status at baseline who received daily or weekly supplementation (aOR 0.30, 0.17 to 0.53).</p></sec>
<sec>
<title>Added value of this study</title>
<p>Our meta-analysis of aggregate data from 46,331 participants in 42 randomised controlled trials, stratified by baseline 25(OH)D concentration, provides an updated estimate of the protective effects of vitamin D against acute respiratory infection overall, and in sub-groups defined by baseline vitamin D status and dosing frequency, amount and duration.</p></sec>
<sec>
<title>Implications of all the available evidence</title>
<p>Overall, vitamin D reduced the risk of having one or more acute respiratory infections (OR 0.91, 0.84 to 0.99), but there was evidence of significant heterogeneity across trials (P for heterogeneity 0.01). A funnel plot showed left-sided asymmetry, which may reflect publication bias and/or heterogeneity of effect across trials. No statistically significant effect of vitamin D was seen for any of the sub-groups defined by baseline 25(OH)D concentration. However, protective effects were seen in trials where vitamin D was given using a daily dosing regimen (OR 0.75, 0.61 to 0.93); at daily dose equivalents of 400-1000 IU (OR 0.70, 0.55 to 0.89); and for a duration of &#x2264;12 months (OR 0.82, 0.72 to 0.93). The relevance of these findings to COVID-19 is not known and requires investigation.</p></sec></sec>
</abstract>
<counts>
<page-count count="57"/>
</counts>
</article-meta>
<notes>
<notes notes-type="competing-interest-statement">
<title>Competing Interest Statement</title><p>The authors have declared no competing interest.</p></notes>
<notes notes-type="clinical-trial-statement">
<title>Clinical Trial</title><p>CRD42020190633</p></notes>
<notes notes-type="clinical-protocols-statement">
<title>Clinical Protocols</title><p>
<ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/PROSPEROFILES/190633_PROTOCOL_20200608.pdf">https://www.crd.york.ac.uk/PROSPEROFILES/190633_PROTOCOL_20200608.pdf</ext-link>
</p></notes>
<notes notes-type="financial-disclosure">
<title>Funding Statement</title><p>No external funding was received.</p></notes>
<notes notes-type="disclosures">
<title>Author Declarations</title><p>I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.</p><p>Yes</p><p>The details of the IRB/oversight body that provided approval or exemption for the research described are given below:</p><p>Ethical permission to contribute data from primary trials was required and obtained for studies by Camargo et al (The Ethics Review Committee of the Mongolian Ministry of Health), Murdoch et al (Southern Health and Disability Ethics Committee, ref. URB/09/10/050/AM02), Rees et al (Committee for the Protection of Human Subjects, Dartmouth College, USA; Protocol # 24381), Tachimoto et al (Ethics committee of the Jikei University School of Medicine, ref 26-333: 7839), Tran et al (QIMR Berghofer Medical Research Institute Human Research Ethics Committee, P1570) and Urashima et al (Ethics committee of the Jikei University School of Medicine, ref 26-333: 7839).</p><p>All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.</p><p>Yes</p><p>I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).</p><p>Yes</p><p>I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.</p><p>Yes</p></notes>
<fn-group content-type="summary-of-updates">
<title>Summary of Updates:</title>
<fn fn-type="update"><p>Main and supplemental files updated in response to reviewer comments</p></fn>
</fn-group>
</notes>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Interest in the potential for vitamin D supplementation to reduce risk of acute respiratory infections (ARI) has increased since the emergence of the COVID-19 pandemic.<sup><xref ref-type="bibr" rid="c1">1</xref></sup> This stems from findings of laboratory studies, showing that vitamin D metabolites support innate immune responses to respiratory viruses,<sup><xref ref-type="bibr" rid="c2">2</xref></sup> together with observational studies reporting independent associations between low circulating levels of 25-hydroxyvitamin D (25[OH]D, the widely accepted biomarker of vitamin D status) and increased risk of ARI caused by other pathogens.<sup><xref ref-type="bibr" rid="c3">3</xref>,<xref ref-type="bibr" rid="c4">4</xref></sup> Randomised controlled trials (RCTs) of vitamin D for the prevention of ARI have produced heterogeneous results, with some showing protection, and others reporting null findings. We previously meta-analysed individual participant data from 10,933 participants in 25 RCTs<sup><xref ref-type="bibr" rid="c5">5</xref>-<xref ref-type="bibr" rid="c29">29</xref></sup> and showed a protective overall effect that was stronger in those with lower baseline 25(OH)D levels, and in trials where vitamin D was administered daily or weekly rather than in more widely spaced bolus doses.<sup><xref ref-type="bibr" rid="c30">30</xref></sup> Since the date of the final literature search performed for that study (December 2015), 20 RCTs with 62,063 participants fulfilling the same eligibility criteria have been completed.<sup><xref ref-type="bibr" rid="c31">31</xref>-<xref ref-type="bibr" rid="c50">50</xref></sup> We therefore sought data from these more recent studies for inclusion in an updated meta-analysis of stratified aggregate (trial-level) data to determine whether vitamin D reduced ARI risk overall, and to evaluate whether effects of vitamin D on ARI risk varied according to baseline 25(OH)D concentration and/or dosing regimen (frequency, dose size, and trial duration).</p>
</sec>
<sec id="s2">
<title>Methods</title>
<sec id="s2a">
<title>Protocol, Registration and Ethical Approvals</title>
<p>Methods were pre-specified in a protocol that was registered with the PROSPERO International Prospective Register of Systematic Reviews (<ext-link ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=190633">https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=190633</ext-link>). Research Ethics Committee approval to conduct this meta-analysis was not required in the UK; local ethical permission to contribute data from primary trials was required and obtained for studies by Camargo <italic>et al</italic><sup><xref ref-type="bibr" rid="c13">13</xref></sup> (The Ethics Review Committee of the Mongolian Ministry of Health), Murdoch <italic>et al</italic><sup><xref ref-type="bibr" rid="c14">14</xref></sup> (Southern Health and Disability Ethics Committee, ref. URB/09/10/050/AM02), Rees <italic>et al</italic><sup><xref ref-type="bibr" rid="c17">17</xref></sup> (Committee for the Protection of Human Subjects, Dartmouth College, USA; Protocol # 24381), Tachimoto <italic>et al</italic><sup><xref ref-type="bibr" rid="c28">28</xref></sup> (Ethics committee of the Jikei University School of Medicine, ref 26-333: 7839), Tran <italic>et al</italic><sup><xref ref-type="bibr" rid="c18">18</xref></sup> (QIMR Berghofer Medical Research Institute Human Research Ethics Committee, P1570) and Urashima <italic>et al</italic><sup><xref ref-type="bibr" rid="c6">6</xref>,<xref ref-type="bibr" rid="c20">20</xref></sup> (Ethics committee of the Jikei University School of Medicine, ref 26-333: 7839).</p>
</sec>
<sec id="s2b">
<title>Eligibility Criteria</title>
<p>Randomised, double-blind, trials of supplementation with vitamin D<sub>3</sub>, vitamin D<sub>2</sub> or 25(OH)D of any duration, with a placebo or low-dose vitamin D control, were eligible for inclusion if they had been approved by a Research Ethics Committee and if data on incidence of ARI were collected prospectively and pre-specified as an efficacy outcome. The latter requirement was imposed in order to minimise misclassification bias (prospectively designed instruments to capture ARI events were deemed more likely to be sensitive and specific for this outcome). Studies reporting results of long-term follow-up of primary RCTs were excluded.</p>
</sec>
<sec id="s2c">
<title>Study Identification and Selection</title>
<p>Two investigators (ARM and DAJ) searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science and the ClinicalTrials.gov registry using the electronic search strategies described in the Methods Section of Supplementary Material. Searches were regularly updated up to and including 1<sup>st</sup> May 2020. No language restrictions were imposed. These searches were supplemented by searching review articles and reference lists of trial publications. Collaborators were asked if they knew of any additional trials. Three investigators (DAJ, CAC and ARM) determined which trials met the eligibility criteria.</p>
</sec>
<sec id="s2d">
<title>Data Collection Processes</title>
<p>Summary data from trials which contributed to our previous meta-analysis of individual participant data<sup><xref ref-type="bibr" rid="c30">30</xref></sup> were extracted from our central database, with permission from the Principal Investigators. Summary data relating to the primary outcome (overall and by sub-group) and secondary outcomes (overall only) from newly identified trials were requested from Principal Investigators. On receipt, they were assessed for consistency with associated publications. Study authors were contacted to provide missing data and to resolve any queries arising from these consistency checks. Once queries had been resolved, clean summary data were uploaded to the study database, which was held in STATA IC v14.2 (StataCorp, College Station, TX).</p>
<p>Data relating to study characteristics were extracted for the following variables: study setting, eligibility criteria, 25(OH)D assay and levels, details of intervention and control regimens, trial duration, case definitions for ARI and number entering primary analysis (after randomisation). Follow-up summary data were requested for the proportions of participants experiencing one or more ARI during the trial, both overall and stratified by baseline serum 25(OH)D concentration, where this was available. We also requested summary data on the proportions of participants who experienced one or more of the following events during the trial: upper respiratory infection (URI); lower respiratory infection (LRI); Emergency Department attendance and/or hospital admission for ARI; death due to ARI or respiratory failure; use of antibiotics to treat an ARI; absence from work or school due to ARI; a serious adverse event; death due to any cause; and potential adverse reactions to vitamin D (hypercalcaemia and renal stones).</p>
</sec>
<sec id="s2e">
<title>Risk of Bias Assessment for Individual Studies</title>
<p>We used the Cochrane Collaboration Risk of Bias tool<sup><xref ref-type="bibr" rid="c51">51</xref></sup> to assess the following variables: sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors, completeness of outcome data, evidence of selective outcome reporting and other potential threats to validity. Study quality was assessed independently by two investigators (ARM and DAJ), except for the five trials for which DAJ and/or ARM were investigators, which were assessed by CAC. Discrepancies were resolved by consensus.</p>
</sec>
<sec id="s2f">
<title>Definition of outcomes</title>
<p>The primary outcome of the meta-analysis was the proportion of participants experiencing one or more ARIs, with the definition of ARI encompassing events classified as URI, LRI and ARI of unclassified location (i.e. infection of the upper and/or lower respiratory tract). Secondary outcomes were incidence of URI and LRI, analysed separately; incidence of Emergency Department attendance and/or hospital admission for ARI; death due to ARI or respiratory failure; use of antibiotics to treat an ARI; absence from work or school due to ARI; incidence of serious adverse events; death due to any cause; and incidence of potential adverse reactions to vitamin D (hypercalcaemia and renal stones).</p>
</sec>
<sec id="s2g">
<title>Synthesis Methods</title>
<p>Data were analysed by DAJ; results were checked and verified by JDS. Our meta-analysis approach followed published guidelines.<sup><xref ref-type="bibr" rid="c52">52</xref></sup> The primary comparison was of participants randomised to vitamin D vs. placebo: this was performed for all of the outcomes listed above. For trials that included higher-dose, lower-dose and placebo arms, data from higher-dose and lower-dose arms were pooled for analysis of the primary comparison. A secondary comparison of participants randomised to higher vs. lower doses of vitamin D was performed for the primary outcome only. A log odds ratio and its standard error was calculated for each outcome within each trial from the proportion of participants experiencing one or more events in the intervention vs. control arm. These were meta-analysed in a random effects model using the Metan package<sup><xref ref-type="bibr" rid="c53">53</xref></sup> within STATA IC v14.2 to obtain a pooled odds ratio with a 95% confidence interval and a measure of heterogeneity summarized by the I<sup>2</sup> statistic and its corresponding P value.</p>
</sec>
<sec id="s2h">
<title>Exploration of variation in effects</title>
<p>To explore reasons for heterogeneity of effect of the intervention between trials we performed a stratified analysis according to baseline vitamin D status (serum 25[OH]D &#x003C;25 <italic>vs</italic>. 25-49.9 <italic>vs</italic>. 50-74.9 <italic>vs</italic>. &#x2265;75 nmol/L) and according to age at baseline (&#x003C;1 <italic>vs</italic>. 1-15.99 <italic>vs</italic>. 16-64.99 <italic>vs</italic>. &#x2265;65 yrs). We additionally conducted sub-group analyses according to vitamin D dosing regimen (administration of daily <italic>vs</italic>. weekly <italic>vs</italic>. monthly or less frequent doses), dose size (daily equivalent &#x003C;400 IU <italic>vs</italic>. 400-1000 IU <italic>vs</italic>. 1001-2000 IU <italic>vs</italic>. &#x003E;2,000 IU), trial duration (&#x2264;12 months <italic>vs</italic>. &#x003E;12 months) and presence of airway disease (trial restricted to participants with asthma <italic>vs</italic>. those restricted to participants with COPD <italic>vs</italic>. those in which participants without airway disease were eligible). The thresholds for baseline 25(OH)D concentration used in sub-group analyses were selected <italic>a priori</italic> on the basis that they represent cut-offs that are commonly used to distinguish profound vitamin D deficiency (&#x003C;25 nmol/L), moderate vitamin D deficiency (25-49.9 nmol/L) and sub-optimal vitamin D status (50-74.9 nmol/L).<sup><xref ref-type="bibr" rid="c54">54</xref></sup> An exploratory analysis restricted to studies with optimal dosing frequency, dose size and duration was also performed.</p>
<p>To investigate factors associated with heterogeneity of effect between subgroups of trials, we performed multivariable meta-regression analysis on trial-level characteristics, namely, dose frequency, dose size and trial duration, to produce an adjusted odds ratio, a 95% confidence interval and a P value for interaction for each factor. Independent variables were dichotomised to create a more parsimonious model (serum 25(OH)D of &#x003C;25 vs. &#x2265;25 nmol/L; administration of daily vs. non-daily doses; daily equivalent of &#x2264;1000 IU vs. &#x003E;1000 IU; and trial duration of &#x2264;12 vs. &#x003E;12 months). The meta-regression analysis excluded data from two trials that included higher-dose, lower-dose and placebo arms,<sup><xref ref-type="bibr" rid="c18">18</xref>,<xref ref-type="bibr" rid="c47">47</xref></sup> since the higher-dose and lower-dose arms spanned the 1,000 IU/day cut-off, rendering them unclassifiable for the purposes of this analysis.</p>
</sec>
<sec id="s2i">
<title>Quality Assessment Across Studies</title>
<p>For the primary analysis, the likelihood of publication bias was investigated through the construction of a contour-enhanced funnel plot.<sup><xref ref-type="bibr" rid="c55">55</xref></sup> We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias)<sup><xref ref-type="bibr" rid="c56">56</xref></sup> to assess the quality of the body of evidence contributing to analyses of the primary efficacy outcome and major secondary outcomes of our meta-analysis.</p>
</sec>
<sec id="s2j">
<title>Sensitivity analyses</title>
<p>We conducted three exploratory sensitivity analyses for the primary comparison of the primary outcome: one excluded RCTs where risk of bias was assessed as being unclear; one excluded RCTs in which incidence of ARI was not the primary or co-primary outcome; and one substituted diary-defined ARI events (available for 2598 participants) for survey-defined ARI events (available for n=16,000 participants) from the trial by Pham et al.<sup><xref ref-type="bibr" rid="c44">44</xref></sup></p>
</sec>
<sec id="s2k">
<title>Role of the funding source</title>
<p>This study was conducted without external funding.</p>
</sec>
</sec>
<sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Study selection and data obtained</title>
<p>The study selection process is illustrated in <xref rid="fig1" ref-type="fig">Figure 1</xref>. Our search identified a total of 1,528 unique studies that were assessed for eligibility, of which 45 studies with a total of 73,384 randomised participants fulfilled eligibility criteria. Studies for which full text was reviewed prior to exclusion due to ineligibility are listed in <xref rid="tblS1" ref-type="table">Table S1</xref>. Of the 45 eligible studies identified, 34 compared effects of a single vitamin D regimen vs. placebo only,<sup><xref ref-type="bibr" rid="c5">5</xref>-<xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c19">19</xref>,<xref ref-type="bibr" rid="c20">20</xref>,<xref ref-type="bibr" rid="c22">22</xref>,<xref ref-type="bibr" rid="c23">23</xref>,<xref ref-type="bibr" rid="c25">25</xref>-<xref ref-type="bibr" rid="c28">28</xref>,<xref ref-type="bibr" rid="c31">31</xref>,<xref ref-type="bibr" rid="c33">33</xref>,<xref ref-type="bibr" rid="c36">36</xref>,<xref ref-type="bibr" rid="c38">38</xref>,<xref ref-type="bibr" rid="c39">39</xref>,<xref ref-type="bibr" rid="c41">41</xref>-<xref ref-type="bibr" rid="c45">45</xref>,<xref ref-type="bibr" rid="c48">48</xref>-<xref ref-type="bibr" rid="c50">50</xref></sup> 5 compared effects of higher-dose, lower-dose and placebo arms,<sup><xref ref-type="bibr" rid="c18">18</xref>,<xref ref-type="bibr" rid="c21">21</xref>,<xref ref-type="bibr" rid="c24">24</xref>,<xref ref-type="bibr" rid="c40">40</xref>,<xref ref-type="bibr" rid="c47">47</xref></sup> and 6 compared effects of higher-vs. lower-dose regimens of vitamin D only.<sup><xref ref-type="bibr" rid="c29">29</xref>,<xref ref-type="bibr" rid="c32">32</xref>,<xref ref-type="bibr" rid="c34">34</xref>,<xref ref-type="bibr" rid="c35">35</xref>,<xref ref-type="bibr" rid="c37">37</xref>,<xref ref-type="bibr" rid="c46">46</xref></sup> Stratified aggregate data were sought and obtained for all but 3 eligible studies.<sup><xref ref-type="bibr" rid="c48">48</xref>-<xref ref-type="bibr" rid="c50">50</xref></sup> Data for the primary outcome (proportion of participants with one or more ARI) were obtained for 46,331 (98.0%) of 47,262 participants in 42 studies.<sup><xref ref-type="bibr" rid="c5">5</xref>-<xref ref-type="bibr" rid="c17">17</xref>,<xref ref-type="bibr" rid="c31">31</xref>-<xref ref-type="bibr" rid="c47">47</xref></sup></p>
<fig id="fig1" position="float" fig-type="figure">
<label>Figure 1:</label>
<caption><p>Flow chart of study selection</p></caption>
<graphic xlink:href="20152728v2_fig1.tif"/>
</fig>
</sec>
<sec id="s3b">
<title>Study and participant characteristics</title>
<p>Characteristics of the 42 studies contributing data to this meta-analysis and their participants are presented in <xref rid="tbl1" ref-type="table">Table 1</xref>. Trials were conducted in 18 different countries on 5 continents, and enrolled participants of both sexes from birth to 95 years of age. Baseline serum 25(OH)D concentrations were determined in 34 of 42 trials: mean baseline 25(OH)D concentration ranged from 18.9 to 90.9 nmol/L (to convert to ng/ml, divide by 2.496). Forty-one studies administered oral vitamin D3 to participants in the intervention arm, while 1 study administered oral 25(OH)D. Vitamin D was given as monthly to 3-monthly bolus doses in 13 studies; as weekly doses in 6 studies; as daily doses in 21 studies; and as a combination of bolus and daily doses in 2 studies. Trial duration ranged from 8 weeks to 5 years. Incidence of ARI was primary or co-primary outcome for 22 studies, and a secondary outcome for 20 studies.</p>
<table-wrap id="tbl1" orientation="portrait" position="float">
<label>Table 1:</label>
<caption><p>Characteristics of the 42 eligible trials and their participants</p></caption>
<graphic xlink:href="20152728v2_tbl1.tif"/>
<graphic xlink:href="20152728v2_tbl1a.tif"/>
<graphic xlink:href="20152728v2_tbl1b.tif"/>
</table-wrap>
</sec>
<sec id="s3c">
<title>Risk of Bias Within Studies</title>
<p>Details of the risk of bias assessment are provided in <xref rid="tblS2" ref-type="table">supplementary Table S2</xref>. Four trials were assessed as being at unclear risk of bias due to high loss to follow-up. In the trial by Laaksi and colleagues,<sup><xref ref-type="bibr" rid="c8">8</xref></sup> 37% of randomised participants were lost to follow-up. In the trial by Dubnov-Raz and colleagues,<sup><xref ref-type="bibr" rid="c26">26</xref></sup> 52% of participants did not complete all symptom questionnaires. In the unpublished trial by Reyes and colleagues,<sup><xref ref-type="bibr" rid="c47">47</xref></sup> loss to follow-up ranged from 33% to 37% across the three study arms, and in the unpublished trial by Golan-Tripto and colleagues,<sup><xref ref-type="bibr" rid="c46">46</xref></sup> 50% of participants were lost to follow-up. All other trials were assessed as being at low risk of bias for all seven aspects assessed.</p>
</sec>
<sec id="s3d">
<title>Overall Results, Primary Outcome</title>
<p>For the primary comparison of vitamin D vs. placebo control, supplementation resulted in a statistically significant reduction in the proportion of participants experiencing at least one ARI (Odds Ratio [OR] 0.91, 95% Confidence Interval [CI] 0.84 to 0.99; 44,009 participants in 36 studies; <xref rid="fig2" ref-type="fig">Figure 2</xref>, <xref rid="tbl2" ref-type="table">Table 2</xref>; Cates Plot, <xref rid="figS1" ref-type="fig">Figure S1</xref>). Heterogeneity of effect was moderate (I<sup>2</sup> 37.2%, P for heterogeneity 0.01).</p>
<table-wrap id="tbl2" orientation="portrait" position="float">
<label>Table 2:</label>
<caption><title>Placebo controlled RCTs</title>
<p>Proportion of participants experiencing at least one acute respiratory infection, overall and stratified by potential effect-modifiers</p></caption>
<graphic xlink:href="20152728v2_tbl2.tif"/>
</table-wrap>
<fig id="fig2" position="float" fig-type="figure">
<label>Figure 2:</label>
<caption><p>Forest plot of placebo-controlled RCTs reporting proportion of participants experiencing 1 or more acute respiratory infection.</p>
<p>&#x002A;This analysis includes data from the subset of ViDiFlu trial participants who were randomised to vitamin D vs. placebo control. &#x002A;&#x002A;For this trial, participants were asked to report the occurrence of ARI during the one month prior to completing each annual urvey (max surveys=5). The numerator is the number of participants who reported an ARI on at least one survey. The ARI outcomes for participants who completed fewer than 5 surveys and who did not report an ARI (N=2239; 14%) were estimated based on the % affected among those who completed all 5 surveys (N=12152; 76%).</p></caption>
<graphic xlink:href="20152728v2_fig2.tif"/>
</fig>
<p>For the secondary comparison of higher-vs. lower-dose vitamin D, we observed no statistically significant difference in the proportion of participants with at least one ARI (OR 0.87, 95% CI 0.73 to 1.04; 3,047 participants in 11 studies; I<sup>2</sup> 0.0%, P for heterogeneity 0.50; <xref rid="figS2" ref-type="fig">Figure S2</xref>).</p>
</sec>
<sec id="s3e">
<title>Sub-group analyses, Primary Outcome</title>
<p>To investigate reasons for the observed heterogeneity of effect for the primary comparison of vitamin D vs. placebo control, we stratified this analysis by two participant-level factors (baseline vitamin D status and age) and by four trial-level factors (dose frequency, dose size, trial duration, and airway disease comorbidity). Results are presented in <xref rid="tbl2" ref-type="table">Table 2</xref> and <xref rid="figS3" ref-type="fig">Figures S3</xref>-<xref rid="figS8" ref-type="fig">S8</xref>. No statistically significant effect of vitamin D was seen for participants with baseline 25(OH)D &#x003C;25 nmol/L (OR 0.78, 95% CI 0.53 to 1.16; 3,617 participants in 19 studies), 25-49.9 nmol/L (OR 1.03, 95% CI 0.92 to 1.15; 9,167 participants in 28 studies), 50-74.9 nmol (OR 0.90, 95% CI 0.76 to 1.06; 5,417 participants in 29 studies), or &#x2265;75 nmol/L (OR 0.97, 95% CI 0.81 to 1.16; 3,014 participants in 25 studies; <xref rid="figS3" ref-type="fig">Figure S3</xref>). A statistically significant protective effect of vitamin D was seen for participants aged 1-15.9 years (OR 0.71, 95% CI 0.57 to 0.90; 11,871 participants in 15 studies), but not in participants aged &#x003C;1 year (OR 0.95, 95% CI 0.82 to 1.10; 5,697 participants in 5 studies), 16-64.99 years (OR 0.97, 95% CI 0.93 to 1.09; 9,603 participants in 21 studies), or &#x2265;65 years (OR 0.96, 95% CI 0.90 to 1.02; 16,983 participants in 16 studies; <xref rid="figS7" ref-type="fig">Figure S7</xref>).</p>
<p>With regard to dosing frequency, a statistically significant protective effect was seen for trials where vitamin D was given daily (OR 0.75, 95% CI 0.61 to 0.93; 4,005 participants in 18 studies), but not for trials in which it was given weekly (OR 0.97, 95% CI 0.88 to 1.06; 12,756 participants in 6 studies), or monthly to 3-monthly (OR 0.98, 95% CI 0.93 to 1.03; 27,248 participants in 12 studies; <xref rid="figS4" ref-type="fig">Figure S4</xref>). Statistically significant protective effects of the intervention were also seen in trials where vitamin D was administered at daily equivalent doses of 400-1000 IU (OR 0.70, 95% CI 0.55 to 0.89; 2,305 participants in 10 studies), but not where the daily dose equivalent was &#x003C;400 IU (OR 0.65, 95% CI 0.31 to 1.37; 2,308 participants in 2 studies), 1001-2000 IU (OR 0.97, 95% CI 0.92 to 1.03; 31,702 participants in 15 studies), or &#x003E;2000 IU (OR 1.05, 95% CI 0.84 to 1.31; 6,906 participants in 7 studies; <xref rid="figS5" ref-type="fig">Figure S5</xref>). Statistically significant protective effects were also seen for trials with a duration of &#x2264;12 months (OR 0.82, 95% CI 0.72 to 0.93; 9,255 participants in 29 studies) but not in those lasting &#x003E;12 months (OR 0.99, 95% CI 0.95 to 1.04; 34,754 participants in 7 studies; <xref rid="figS6" ref-type="fig">Figure S6</xref>).</p>
<p>Finally, statistically significant protective effects were also seen for trials that were not restricted to participants with asthma or COPD (OR 0.91, 95% CI 0.84 to 0.99; 42,799 participants in 30 studies), but not in trials that exclusively enrolled participants with asthma (OR 0.73, 95% CI 0.36 to 1.49; 795 participants in 4 studies), or COPD (OR 1.01, 95% 0.68 to 1.51; 415 participants in 2 studies; <xref rid="figS8" ref-type="fig">Figure S8</xref>).</p>
<p>An exploratory analysis restricted to eight placebo-controlled trials investigating effects of daily dosing at doses of 400-1000 IU/day with duration &#x2264;12 months (for which mean baseline 25(OH)D level ranged from 54.8 nmol/L to 88.9 nmol/L) showed a statistically significant reduction in the proportion of participants experiencing at least one ARI (OR 0.58, 95% CI 0.45 to 0.75; 1,232 participants in 8 studies; <xref rid="figS9" ref-type="fig">Figure S9</xref>; Cates Plot, <xref rid="figS1" ref-type="fig">Figure S1</xref>). Heterogeneity of effect for this exploratory analysis was low (I<sup>2</sup> 0.0%, P for heterogeneity 0.67).</p>
</sec>
<sec id="s3f">
<title>Multivariable Meta-Regression Analysis</title>
<p>Multivariable meta-regression analysis of trial-level sub-groups did not identify a statistically significant interaction between allocation to vitamin D vs. placebo and dose frequency, size or trial duration (<xref rid="tblS3" ref-type="table">Table S3</xref>).</p>
</sec>
<sec id="s3g">
<title>Secondary outcomes</title>
<p>Meta-analysis of secondary outcomes was performed for results of placebo-controlled trials only; results are presented in <xref rid="tbl3" ref-type="table">Table 3</xref>. Overall, without consideration of participant-or trial-level factors, vitamin D supplementation did not have a statistically significant effect on the proportion of participants with one or more URI, LRI, courses of antimicrobials for ARI, work/school absences due to ARI, hospitalisations or emergency department attendances for ARI, serious adverse events of any cause, death due to ARI or respiratory failure, death due to any cause, or episodes of hypercalcaemia or renal stones.</p>
<table-wrap id="tbl3" orientation="portrait" position="float">
<label>Table 3:</label>
<caption><title>Placebo-controlled studies</title>
<p>Secondary outcomes</p></caption>
<graphic xlink:href="20152728v2_tbl3.tif"/>
</table-wrap>
</sec>
<sec id="s3h">
<title>Risk of bias across studies</title>
<p>A funnel plot for the proportion of participants experiencing at least one ARI (<xref rid="figS10" ref-type="fig">Figure S10</xref>) showed left-sided asymmetry, confirmed with an Egger&#x2019;s regression test<sup><xref ref-type="bibr" rid="c57">57</xref></sup> (P=0.008). This might reflect heterogeneity of effect across trials, or publication bias arising from omission of small trials showing non-protective effects of vitamin D from the meta-analysis.<sup><xref ref-type="bibr" rid="c58">58</xref></sup> Given the latter possibility, the quality of the body of evidence contributing to analyses of the primary efficacy outcome and major secondary outcomes was downgraded to moderate (<xref rid="tblS4" ref-type="table">Table S4</xref>).</p>
</sec>
<sec id="s3i">
<title>Sensitivity Analyses</title>
<p>Results of exploratory sensitivity analyses are presented in <xref rid="tblS5" ref-type="table">Table S5</xref>. Meta-analysis of the proportion of participants in placebo-controlled trials experiencing at least one ARI, excluding 4 studies assessed as being at unclear risk of bias,<sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c26">26</xref>,<xref ref-type="bibr" rid="c46">46</xref>,<xref ref-type="bibr" rid="c47">47</xref></sup> revealed protective effects of vitamin D supplementation consistent with the main analysis (OR 0.93, 95% CI 0.86 to 1.00; 43,626 participants in 33 studies). Sensitivity analysis for the same outcome, excluding 18 placebo-controlled trials that investigated ARI as a secondary outcome, did not show a statistically significant protective effect (OR 0.89, 95% CI 0.77 to 1.03; 7,537 participants in 18 studies). A sensitivity analysis for the same outcome, substituting diary-defined ARI events (available for 2598 participants) for survey-defined ARI events (available for n=16,000 participants) in the trial by Pham et al<sup><xref ref-type="bibr" rid="c44">44</xref></sup> revealed protective effects of vitamin D supplementation consistent with the main analysis (OR 0.90, 95% CI 0.83 to 0.99; 30,607 participants in 36 studies).</p>
</sec>
</sec>
<sec id="s4">
<title>Discussion</title>
<p>This updated meta-analysis of RCTs of vitamin D supplementation for the prevention of ARI includes data from an additional 17 studies completed since December 2015, when we performed the final literature search for our prior individual participant data meta-analysis.<sup><xref ref-type="bibr" rid="c30">30</xref></sup> For expediency during the COVID-19 pandemic, we used a trial-level approach for this update, which includes data from a total of 46,331 participants in 42 trials. Overall, we report a modest statistically significant protective effect of vitamin D supplementation, as compared with placebo (OR 0.91, 95% CI 0.84 to 0.99). As expected, there was significant heterogeneity (P=0.01) across trials, which might have led to an under-estimate of the protective effect, and contributed to the asymmetry observed in the funnel plot.<sup><xref ref-type="bibr" rid="c58">58</xref></sup> Alternatively, left-sided asymmetry in the funnel plot may reflect publication bias, which might have led to an over-estimate of the protective effect. In contrast to findings of our previous meta-analysis,<sup><xref ref-type="bibr" rid="c30">30</xref></sup> we did not observed enhanced protection in those with the lowest 25(OH)D levels at baseline. However, there was evidence that efficacy of vitamin D supplementation varied according to dosing regimen and trial duration, with protective effects associated with daily administration of doses of 400-1000 IU vitamin D given for &#x2264;12 months. An exploratory analysis restricted to data from 8 trials fulfilling these design criteria revealed a larger protective effect (OR 0.58, 95% CI 0.45 to 0.75) without significant heterogeneity across trials (P for heterogeneity 0.67).</p>
<p>The magnitude of the overall protective effect seen in the current analysis (OR 0.91, 95% CI 0.84 to 0.99) is modest, and similar to the value reported in our previous meta-analysis of individual participant data (adjusted OR 0.88, 95% CI 0.81 to 0.96).<sup><xref ref-type="bibr" rid="c30">30</xref></sup> In keeping with our previous study, the point estimate for this effect was lower among those with baseline 25(OH)D &#x003C;25 nmol/L than in those with higher baseline vitamin D status. However, in contrast to our previous finding, a statistically significant protective effect of vitamin D was not seen in those with the lowest 25(OH)D concentrations. This difference reflects the inclusion of null data from four new RCTs in which vitamin D was given in relatively high doses at weekly or monthly intervals over 2-5 years. <sup><xref ref-type="bibr" rid="c41">41</xref>,<xref ref-type="bibr" rid="c42">42</xref>,<xref ref-type="bibr" rid="c44">44</xref>,<xref ref-type="bibr" rid="c45">45</xref></sup> Null results of these studies contrast with protective effects reported from earlier trials in which smaller daily doses of vitamin D were given over shorter periods. <sup><xref ref-type="bibr" rid="c8">8</xref>,<xref ref-type="bibr" rid="c9">9</xref>,<xref ref-type="bibr" rid="c13">13</xref>,<xref ref-type="bibr" rid="c16">16</xref></sup> These differing findings suggest that the frequency, amount and duration of vitamin D supplementation may be key determinants of its protective efficacy. In keeping with this hypothesis, statistically significant protective effects of vitamin D were seen for meta-analysis of trials where vitamin D was given daily; where it was given at doses of 400-1000 IU/day; and where it was given for 12 months or less. When results of trials that investigated daily administration of 400-1000 IU over &#x2264;12 months were pooled in an exploratory meta-analysis, a protective effect was seen (OR 0.58, 95% CI 0.45 to 0.75) with low heterogeneity (I<sup>2</sup> 0.0%, P for heterogeneity 0.67). Greater protective efficacy of lower vs higher doses of vitamin D might reflect deleterious effects of higher-dose vitamin D on its own metabolism, or on host responses to respiratory pathogens: head-to-head mechanistic studies in individuals randomised to different regimens of vitamin D supplementation are needed to investigate this issue.</p>
<p>The current study has several strengths: it contains the very latest RCT data available in this fast-moving field, including findings from three large phase 3 trials published in 2020<sup><xref ref-type="bibr" rid="c41">41</xref>,<xref ref-type="bibr" rid="c42">42</xref>,<xref ref-type="bibr" rid="c44">44</xref></sup> as well as some as-yet unpublished studies.<sup><xref ref-type="bibr" rid="c46">46</xref>,<xref ref-type="bibr" rid="c47">47</xref></sup> The inclusion of additional studies allowed us to analyse results of placebo-controlled studies vs. high-dose / low-dose studies separately, and gave us the power to investigate reasons for heterogeneity of effect observed across trials. For example, we could distinguish the effects of daily vs. weekly dosing, which were previously pooled.<sup><xref ref-type="bibr" rid="c30">30</xref></sup></p>
<p>Our work also has limitations. Given the need to generate a rapid update of our previous work in the context of the COVID-19 pandemic, we meta-analysed aggregate (trial-level) data, rather than individual participant data; this allowed us to proceed rapidly, without the delays introduced by the need to establish multiple data sharing agreements. However, we did contact authors to get unpublished estimates of effect that were stratified by pre-defined baseline 25(OH)D levels, harmonised across studies: thus, we were able to provide accurate data for the major participant-level effect-modifier of interest. Despite the large number of trials overall, relatively few compared effects of lower-vs. higher-dose vitamin D: our power for this secondary comparison was therefore limited. We lacked the individual participant data to investigate race/ethnicity and obesity as potential effect-modifiers. We also could not account for other factors that might influence the efficacy of vitamin D supplements for ARI prevention (e.g., taking the supplement with or without food) or secular trends that would influence trials, such as the increased societal use of vitamin D supplements;<sup><xref ref-type="bibr" rid="c59">59</xref></sup> concurrent use of standard dose vitamin D supplements or multivitamins in the &#x201C;placebo&#x201D; group would effectively render these as high-vs. low-dose trials and potentially drive results toward the null. A final limitation relates to the funnel plot, which suggests that the overall effect size may have been over-estimated due to publication bias; we have mitigated this by inclusion of data from unpublished studies identified by searching clinicaltrials.gov where this was obtainable.</p>
<p>In summary, this updated meta-analysis of data from RCTs of vitamin D for the prevention of ARI showed a statistically significant overall protective effect of the intervention. The protective effect was heterogenous across trials; it also may have been over-estimated due to publication bias. In contrast to findings of our previous meta-analysis of individual participant data, we did not see a protective effect of vitamin D supplementation among those with the lowest baseline vitamin D status. The vitamin D dosing regimen of most benefit was daily and used standard doses (e.g., 400 to 1000 IU) for up to 12 months. The relevance of these findings to COVID-19 is not known and requires investigation.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability">
<title>Data Availability</title>
<p>The study dataset is available from <email>d.a.jolliffe@qmul.ac.uk</email>.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>This study was conducted without external funding. DAJ is supported by a Barts Charity Lectureship (ref MGU045). ARM is supported by the United Kingdom Office for Students. The views expressed are those of the authors and not necessarily those of Barts Charity or the Office for Students. Sources of support for individual trials are detailed in Supplementary Material. We thank all the people who participated in primary randomised controlled trials, and the teams who conducted them.</p>
</ack>
<sec id="s5">
<title>Author Contributions</title>
<p>DAJ and ARM wrote the study protocol and designed statistical analyses. DAJ, CAC and ARM assessed eligibility of studies for inclusion and performed risk of bias assessments. Statistical analyses were done by DAJ; results were checked and verified by JDS. DAJ and ARM wrote the first draft of the report. All authors revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved.</p>
</sec>
<sec id="s6">
<title>Competing Interests</title>
<p>All authors have completed the ICMJE uniform disclosure form. No author has had any financial relationship with any organisations that might have an interest in the submitted work in the previous three years. No author has had any other relationship, or undertaken any activity, that could appear to have influenced the submitted work.</p>
</sec>
<sec id="s7">
<title>Transparency Declaration</title>
<p>DAJ and ARM are the manuscript&#x2019;s guarantors and they affirm that this is an honest, accurate, and transparent account of the study being reported and that no important aspects of the study have been omitted. All analyses were pre-specified in the study protocol, other than the exploratory analyses whose results are presented in <xref rid="tbl2" ref-type="table">Table 2</xref> (sub-group analyses by age and presence of asthma/COPD, requested by reviewers), <xref rid="tblS5" ref-type="table">Table S5</xref> and <xref rid="figS7" ref-type="fig">Figure S7</xref>.</p>
</sec>
<sec id="s8">
<title>Data Sharing</title>
<p>the study dataset is available from <email>d.a.jolliffe@qmul.ac.uk</email>.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="c1"><label>1.</label><mixed-citation publication-type="other"><string-name><surname>Lanham-New</surname> <given-names>SA</given-names></string-name>, <string-name><surname>Webb</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Cashman</surname> <given-names>KD</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D and SARS-CoV-2 virus/COVID-19 disease</article-title>. <source>BMJ Nutrition, Prevention &#x0026; Health</source> <year>2020</year>.</mixed-citation></ref>
<ref id="c2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Greiller</surname> <given-names>CL</given-names></string-name>, <string-name><surname>Martineau</surname> <given-names>AR.</given-names></string-name> <article-title>Modulation of the Immune Response to Respiratory Viruses by Vitamin D</article-title>. <source>Nutrients</source> <year>2015</year>; <volume>7</volume>(<issue>6</issue>): <fpage>4240</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="c3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Jolliffe</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Griffiths</surname> <given-names>CJ</given-names></string-name>, <string-name><surname>Martineau</surname> <given-names>AR</given-names></string-name>. <article-title>Vitamin D in the prevention of acute respiratory infection: systematic review of clinical studies</article-title>. <source>J Steroid Biochem Mol Biol</source> <year>2013</year>; <volume>136</volume>: <fpage>321</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Pham</surname> <given-names>H</given-names></string-name>, <string-name><surname>Rahman</surname> <given-names>A</given-names></string-name>, <string-name><surname>Majidi</surname> <given-names>A</given-names></string-name>, <string-name><surname>Waterhouse</surname> <given-names>M</given-names></string-name>, <string-name><surname>Neale</surname> <given-names>RE</given-names></string-name>. <article-title>Acute Respiratory Tract Infection and 25-Hydroxyvitamin D Concentration: A Systematic Review and Meta-Analysis</article-title>. <source>International Journal of Environmental Research and Public Health</source> <year>2019</year>; <volume>16</volume>(<issue>17</issue>).</mixed-citation></ref>
<ref id="c5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Li-Ng</surname> <given-names>M</given-names></string-name>, <string-name><surname>Aloia</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Pollack</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections</article-title>. <source>Epidemiol Infect</source> <year>2009</year>; <volume>137</volume>(<issue>10</issue>): <fpage>1396</fpage>&#x2013;<lpage>404</lpage>.</mixed-citation></ref>
<ref id="c6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Urashima</surname> <given-names>M</given-names></string-name>, <string-name><surname>Segawa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Okazaki</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kurihara</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wada</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ida</surname> <given-names>H.</given-names></string-name> <article-title>Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren</article-title>. <source>Am J Clin Nutr</source> <year>2010</year>; <volume>91</volume>(<issue>5</issue>): <fpage>1255</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Manaseki-Holland</surname> <given-names>S</given-names></string-name>, <string-name><surname>Qader</surname> <given-names>G</given-names></string-name>, <string-name><surname>Isaq Masher</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial</article-title>. <source>Trop Med Int Health</source> <year>2010</year>; <volume>15</volume>(<issue>10</issue>): <fpage>1148</fpage>&#x2013;<lpage>55</lpage>.</mixed-citation></ref>
<ref id="c8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Laaksi</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ruohola</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Mattila</surname> <given-names>V</given-names></string-name>, <string-name><surname>Auvinen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ylikomi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Pihlajamaki</surname> <given-names>H.</given-names></string-name> <article-title>Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men</article-title>. <source>J Infect Dis</source> <year>2010</year>; <volume>202</volume>(<issue>5</issue>): <fpage>809</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Majak</surname> <given-names>P</given-names></string-name>, <string-name><surname>Olszowiec-Chlebna</surname> <given-names>M</given-names></string-name>, <string-name><surname>Smejda</surname> <given-names>K</given-names></string-name>, <string-name><surname>Stelmach</surname> <given-names>I.</given-names></string-name> <article-title>Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection</article-title>. <source>J Allergy Clin Immunol</source> <year>2011</year>; <volume>127</volume>(<issue>5</issue>): <fpage>1294</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Trilok Kumar</surname> <given-names>G</given-names></string-name>, <string-name><surname>Sachdev</surname> <given-names>HS</given-names></string-name>, <string-name><surname>Chellani</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial</article-title>. <source>BMJ</source> <year>2011</year>; <volume>342</volume>: <fpage>d2975</fpage>.</mixed-citation></ref>
<ref id="c11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Lehouck</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mathieu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Carremans</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial</article-title>. <source>Ann Intern Med</source> <year>2012</year>; <volume>156</volume>(<issue>2</issue>): <fpage>105</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="c12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Manaseki-Holland</surname> <given-names>S</given-names></string-name>, <string-name><surname>Maroof</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Bruce</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial</article-title>. <source>Lancet</source> <year>2012</year>; <volume>379</volume>(<issue>9824</issue>): <fpage>1419</fpage>&#x2013;<lpage>27</lpage>.</mixed-citation></ref>
<ref id="c13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Camargo</surname> <given-names>CA</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Ganmaa</surname> <given-names>D</given-names></string-name>, <string-name><surname>Frazier</surname> <given-names>AL</given-names></string-name>, <etal>et al.</etal> <article-title>Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia</article-title>. <source>Pediatrics</source> <year>2012</year>; <volume>130</volume>(<issue>3</issue>): <fpage>e561</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Murdoch</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Slow</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chambers</surname> <given-names>ST</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial</article-title>. <source>JAMA</source> <year>2012</year>; <volume>308</volume>(<issue>13</issue>): <fpage>1333</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Bergman</surname> <given-names>P</given-names></string-name>, <string-name><surname>Norlin</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Hansen</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study</article-title>. <source>BMJ Open</source> <year>2012</year>; <volume>2</volume>(<issue>6</issue>): <fpage>e001663</fpage>.</mixed-citation></ref>
<ref id="c16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Marchisio</surname> <given-names>P</given-names></string-name>, <string-name><surname>Consonni</surname> <given-names>D</given-names></string-name>, <string-name><surname>Baggi</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D supplementation reduces the risk of acute otitis media in otitis-prone children</article-title>. <source>Pediatr Infect Dis J</source> <year>2013</year>; <volume>32</volume>(<issue>10</issue>): <fpage>1055</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c17"><label>17.</label><mixed-citation publication-type="other"><string-name><surname>Rees</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Hendricks</surname> <given-names>K</given-names></string-name>, <string-name><surname>Barry</surname> <given-names>EL</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D3 Supplementation and Upper Respiratory Tract Infections in a Randomized, Controlled Trial</article-title>. <source>Clin Infect Dis</source> <year>2013</year>.</mixed-citation></ref>
<ref id="c18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Tran</surname> <given-names>B</given-names></string-name>, <string-name><surname>Armstrong</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Ebeling</surname> <given-names>PR</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial</article-title>. <source>Am J Clin Nutr</source> <year>2014</year>; <volume>99</volume>(<issue>1</issue>): <fpage>156</fpage>&#x2013;<lpage>61</lpage>.</mixed-citation></ref>
<ref id="c19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Goodall</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Granados</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Luinstra</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial</article-title>. <source>BMC Infectious Diseases</source> <year>2014</year>; <volume>14</volume>: <fpage>273</fpage>.</mixed-citation></ref>
<ref id="c20"><label>20.</label><mixed-citation publication-type="journal"><string-name><surname>Urashima</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mezawa</surname> <given-names>H</given-names></string-name>, <string-name><surname>Noya</surname> <given-names>M</given-names></string-name>, <string-name><surname>Camargo</surname> <given-names>CA</given-names>, <suffix>Jr.</suffix></string-name> <article-title>Effects of vitamin D supplements on influenza A illness during the 2009 H1N1 pandemic: a randomized controlled trial</article-title>. <source>Food &#x0026; Function</source> <year>2014</year>; <volume>5</volume>(<issue>9</issue>): <fpage>2365</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="c21"><label>21.</label><mixed-citation publication-type="other"><string-name><surname>Grant</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Kaur</surname> <given-names>S</given-names></string-name>, <string-name><surname>Waymouth</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial</article-title>. <source>Acta Paediatr</source> <year>2014</year>.</mixed-citation></ref>
<ref id="c22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Martineau</surname> <given-names>AR</given-names></string-name>, <string-name><surname>James</surname> <given-names>WY</given-names></string-name>, <string-name><surname>Hooper</surname> <given-names>RL</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial</article-title>. <source>The Lancet Respiratory Medicine</source> <year>2015</year>; <volume>3</volume>(<issue>2</issue>): <fpage>120</fpage>&#x2013;<lpage>30</lpage>.</mixed-citation></ref>
<ref id="c23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Martineau</surname> <given-names>AR</given-names></string-name>, <string-name><surname>MacLaughlin</surname> <given-names>BD</given-names></string-name>, <string-name><surname>Hooper</surname> <given-names>RL</given-names></string-name>, <etal>et al.</etal> <article-title>Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs)</article-title>. <source>Thorax</source> <year>2015</year>; <volume>70</volume>(<issue>5</issue>): <fpage>451</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c24"><label>24.</label><mixed-citation publication-type="journal"><string-name><surname>Martineau</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Hanifa</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Witt</surname> <given-names>KD</given-names></string-name>, <etal>et al.</etal> <article-title>Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu)</article-title>. <source>Thorax</source> <year>2015</year>; <volume>70</volume>(<issue>10</issue>): <fpage>953</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="c25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Simpson</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>van der Mei</surname> <given-names>I</given-names></string-name>, <string-name><surname>Stewart</surname> <given-names>N</given-names></string-name>, <string-name><surname>Blizzard</surname> <given-names>L</given-names></string-name>, <string-name><surname>Tettey</surname> <given-names>P</given-names></string-name>, <string-name><surname>Taylor</surname> <given-names>B.</given-names></string-name> <article-title>Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT</article-title>. <source>BMC Nutrition</source> <year>2015</year>; <volume>1</volume>(<issue>7</issue>).</mixed-citation></ref>
<ref id="c26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Dubnov-Raz</surname> <given-names>G</given-names></string-name>, <string-name><surname>Rinat</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hemila</surname> <given-names>H</given-names></string-name>, <string-name><surname>Choleva</surname> <given-names>L</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Constantini</surname> <given-names>NW</given-names></string-name>. <article-title>Vitamin D supplementation and upper respiratory tract infections in adolescent swimmers: a randomized controlled trial</article-title>. <source>Pediatric Exercise Science</source> <year>2015</year>; <volume>27</volume>(<issue>1</issue>): <fpage>113</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="c27"><label>27.</label><mixed-citation publication-type="journal"><string-name><surname>Denlinger</surname> <given-names>LC</given-names></string-name>, <string-name><surname>King</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Cardet</surname> <given-names>JC</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D Supplementation and the Risk of Colds in Patients with Asthma</article-title>. <source>Am J Respir Crit Care Med</source> <year>2016</year>; <volume>193</volume>(<issue>6</issue>): <fpage>634</fpage>&#x2013;<lpage>41</lpage>.</mixed-citation></ref>
<ref id="c28"><label>28.</label><mixed-citation publication-type="other"><string-name><surname>Tachimoto</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mezawa</surname> <given-names>H</given-names></string-name>, <string-name><surname>Segawa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Akiyama</surname> <given-names>N</given-names></string-name>, <string-name><surname>Ida</surname> <given-names>H</given-names></string-name>, <string-name><surname>Urashima</surname> <given-names>M.</given-names></string-name> <article-title>Improved Control of Childhood Asthma with Low-Dose, Short-Term Vitamin D Supplementation: A Randomized, Double-Blind, Placebo-Controlled Trial</article-title>. <source>Allergy</source> <year>2016</year>.</mixed-citation></ref>
<ref id="c29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Ginde</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Blatchford</surname> <given-names>P</given-names></string-name>, <string-name><surname>Breese</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial</article-title>. <source>J Am Geriatr Soc</source> <year>2017</year>; <volume>65</volume>(<issue>3</issue>): <fpage>496</fpage>&#x2013;<lpage>503</lpage>.</mixed-citation></ref>
<ref id="c30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Martineau</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Jolliffe</surname> <given-names>DA</given-names></string-name>, <string-name><surname>Hooper</surname> <given-names>RL</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data</article-title>. <source>BMJ</source> <year>2017</year>; <volume>356</volume>: <fpage>i6583</fpage>.</mixed-citation></ref>
<ref id="c31"><label>31.</label><mixed-citation publication-type="journal"><string-name><surname>Gupta</surname> <given-names>P</given-names></string-name>, <string-name><surname>Dewan</surname> <given-names>P</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D Supplementation for Treatment and Prevention of Pneumonia in Under-five Children: A Randomized Double-blind Placebo Controlled Trial</article-title>. <source>Indian Pediatr</source> <year>2016</year>; <volume>53</volume>(<issue>11</issue>): <fpage>967</fpage>&#x2013;<lpage>76</lpage>.</mixed-citation></ref>
<ref id="c32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Aglipay</surname> <given-names>M</given-names></string-name>, <string-name><surname>Birken</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Parkin</surname> <given-names>PC</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children</article-title>. <source>JAMA</source> <year>2017</year>; <volume>318</volume>(<issue>3</issue>): <fpage>245</fpage>&#x2013;<lpage>54</lpage>.</mixed-citation></ref>
<ref id="c33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Arihiro</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nakashima</surname> <given-names>A</given-names></string-name>, <string-name><surname>Matsuoka</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease</article-title>. <source>Inflamm Bowel Dis</source> <year>2019</year>; <volume>25</volume>(<issue>6</issue>): <fpage>1088</fpage>&#x2013;<lpage>95</lpage>.</mixed-citation></ref>
<ref id="c34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Hibbs</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kerns</surname> <given-names>LA</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial</article-title>. <source>JAMA</source> <year>2018</year>; <volume>319</volume>(<issue>20</issue>): <fpage>2086</fpage>&#x2013;<lpage>94</lpage>.</mixed-citation></ref>
<ref id="c35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname> <given-names>MT</given-names></string-name>, <string-name><surname>Kattan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fennoy</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal> <article-title>Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease</article-title>. <source>Blood Adv</source> <year>2018</year>; <volume>2</volume>(<issue>9</issue>): <fpage>969</fpage>&#x2013;<lpage>78</lpage>.</mixed-citation></ref>
<ref id="c36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Loeb</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dang</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Thiem</surname> <given-names>VD</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of Vitamin D supplementation to reduce respiratory infections in children and adolescents in Vietnam: A randomized controlled trial</article-title>. <source>Influenza Other Respir Viruses</source> <year>2019</year>; <volume>13</volume>(<issue>2</issue>): <fpage>176</fpage>&#x2013;<lpage>83</lpage>.</mixed-citation></ref>
<ref id="c37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Rosendahl</surname> <given-names>J</given-names></string-name>, <string-name><surname>Valkama</surname> <given-names>S</given-names></string-name>, <string-name><surname>Holmlund-Suila</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of Higher vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy Infants: A Randomized Clinical Trial</article-title>. <source>JAMA Pediatrics</source> <year>2018</year>; <volume>172</volume>(<issue>7</issue>): <fpage>646</fpage>&#x2013;<lpage>54</lpage>.</mixed-citation></ref>
<ref id="c38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Shimizu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ito</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yui</surname> <given-names>K</given-names></string-name>, <string-name><surname>Egawa</surname> <given-names>K</given-names></string-name>, <string-name><surname>Orimo</surname> <given-names>H.</given-names></string-name> <article-title>Intake of 25-Hydroxyvitamin D3 Reduces Duration and Severity of Upper Respiratory Tract Infection: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study</article-title>. <source>J Nutr Health Aging</source> <year>2018</year>; <volume>22</volume>(<issue>4</issue>): <fpage>491</fpage>&#x2013;<lpage>500</lpage>.</mixed-citation></ref>
<ref id="c39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Aloia</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Islam</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mikhail</surname> <given-names>M.</given-names></string-name> <article-title>Vitamin D and Acute Respiratory Infections-The PODA Trial</article-title>. <source>Open Forum Infectious Diseases</source> <year>2019</year>; <volume>6</volume>(<issue>9</issue>): <fpage>ofz228</fpage>.</mixed-citation></ref>
<ref id="c40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Hauger</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ritz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mortensen</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Winter cholecalciferol supplementation at 55 degrees N has little effect on markers of innate immune defense in healthy children aged 4-8 years: a secondary analysis from a randomized controlled trial</article-title>. <source>European Journal of Nutrition</source> <year>2019</year>; <volume>58</volume>(<issue>4</issue>): <fpage>1453</fpage>&#x2013;<lpage>62</lpage>.</mixed-citation></ref>
<ref id="c41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Camargo</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Sluyter</surname> <given-names>J</given-names></string-name>, <string-name><surname>Stewart</surname> <given-names>AW</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of monthly high-dose vitamin D supplementation on acute respiratory infections in older adults: A randomized controlled trial</article-title>. <source>Clin Infect Dis</source> <year>2020</year>; <volume>71</volume>: <fpage>311</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="c42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Ganmaa</surname> <given-names>D</given-names></string-name>, <string-name><surname>Uyanga</surname> <given-names>B</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D Supplements and Prevention of Tuberculosis Infection and Disease</article-title>. <source>N Engl J Med</source> <year>2020</year>; <volume>383</volume>: <fpage>359</fpage>&#x2013;<lpage>68</lpage>.</mixed-citation></ref>
<ref id="c43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Mandlik</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mughal</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Khadilkar</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Occurrence of infections in schoolchildren subsequent to supplementation with vitamin D-calcium or zinc: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Nutr Res Pract</source> <year>2020</year>; <volume>14</volume>(<issue>2</issue>): <fpage>117</fpage>&#x2013;<lpage>26</lpage>.</mixed-citation></ref>
<ref id="c44"><label>44.</label><mixed-citation publication-type="other"><string-name><surname>Pham</surname> <given-names>H</given-names></string-name>, <string-name><surname>Waterhouse</surname> <given-names>M</given-names></string-name>, <string-name><surname>Baxter</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial: a randomised controlled trial</article-title>. <source>The Lancet Diabetes &#x0026; Endocrinology</source> <year>2020; in press</year>.</mixed-citation></ref>
<ref id="c45"><label>45.</label><mixed-citation publication-type="journal"><string-name><surname>Rake</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gilham</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bukasa</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>High-dose oral vitamin D supplementation and mortality in people aged 65-84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation</article-title>. <source>Health Technol Assess</source> <year>2020</year>; <volume>24</volume>(<issue>10</issue>): <fpage>1</fpage>&#x2013;<lpage>54</lpage>.</mixed-citation></ref>
<ref id="c46"><label>46.</label><mixed-citation publication-type="website"><string-name><surname>Golan-Tripto</surname> <given-names>I.</given-names></string-name> <source>The Effect of Vitamin D Administration to Premature Infants on Vitamin D Status and Respiratory Morbidity (NCT02404623)</source>. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02404623">https://clinicaltrials.gov/ct2/show/NCT02404623</ext-link>.</mixed-citation></ref>
<ref id="c47"><label>47.</label><mixed-citation publication-type="website"><string-name><surname>Reyes</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Vizcaya</surname> <given-names>C</given-names></string-name>, <string-name><surname>Borzutzky</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <source>Study of Vitamin D for the Prevention of Acute Respiratory Infections in Children (NCT02046577)</source>. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02046577">https://clinicaltrials.gov/ct2/show/NCT02046577</ext-link>.</mixed-citation></ref>
<ref id="c48"><label>48.</label><mixed-citation publication-type="journal"><string-name><surname>Ducharme</surname> <given-names>FM</given-names></string-name>, <string-name><surname>Jensen</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mailhot</surname> <given-names>G</given-names></string-name>, <etal>et al.</etal> <article-title>Impact of two oral doses of 100,000 IU of vitamin D3 in preschoolers with viral-induced asthma: a pilot randomised controlled trial</article-title>. <source>Trials</source> <year>2019</year>; <volume>20</volume>(<issue>1</issue>): <fpage>138</fpage>.</mixed-citation></ref>
<ref id="c49"><label>49.</label><mixed-citation publication-type="website"><string-name><surname>Moreno</surname> <given-names>A.</given-names></string-name> <source>Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life (NCT01875757)</source>.<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01875757">https://clinicaltrials.gov/ct2/show/NCT01875757</ext-link>.</mixed-citation></ref>
<ref id="c50"><label>50.</label><mixed-citation publication-type="other"><string-name><surname>Camargo</surname> <given-names>CA</given-names></string-name>. <source>Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection; NCT01758081)</source>.</mixed-citation></ref>
<ref id="c51"><label>51.</label><mixed-citation publication-type="journal"><string-name><surname>Higgins</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Altman</surname> <given-names>DG</given-names></string-name>, <string-name><surname>Gotzsche</surname> <given-names>PC</given-names></string-name>, <etal>et al.</etal> <article-title>The Cochrane Collaboration&#x2019;s tool for assessing risk of bias in randomised trials</article-title>. <source>BMJ</source> <year>2011</year>; <volume>343</volume>: <fpage>d5928</fpage>.</mixed-citation></ref>
<ref id="c52"><label>52.</label><mixed-citation publication-type="other"><string-name><surname>Higgins JPT</surname> <given-names>TJ</given-names></string-name>, <string-name><surname>Chandler</surname> <given-names>J</given-names></string-name>, <string-name><surname>Cumpston</surname> <given-names>M</given-names></string-name>, <string-name><surname>Li</surname> <given-names>T</given-names></string-name>, <string-name><surname>Page</surname> <given-names>MJ</given-names></string-name>, <string-name><surname>Welch</surname> <given-names>VA</given-names></string-name> (editors). <article-title>Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019)</article-title>. <source>Cochrane</source> <year>2019</year>.</mixed-citation></ref>
<ref id="c53"><label>53.</label><mixed-citation publication-type="other"><string-name><surname>Harris</surname> <given-names>R</given-names></string-name>, <string-name><surname>Bradburn</surname> <given-names>M</given-names></string-name>, <string-name><surname>Deeks</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>METAN: Stata module for fixed and random effects meta-analysis, revised 23 Sep 2010. Statistical Software Components S456798</article-title>. <source>Boston College Department of Economics</source>; <year>2006</year>.</mixed-citation></ref>
<ref id="c54"><label>54.</label><mixed-citation publication-type="journal"><string-name><surname>Pearce</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Cheetham</surname> <given-names>TD</given-names></string-name>. <article-title>Diagnosis and management of vitamin D deficiency</article-title>. <source>BMJ</source> <year>2010</year>; <volume>340</volume>: <fpage>b5664</fpage>.</mixed-citation></ref>
<ref id="c55"><label>55.</label><mixed-citation publication-type="journal"><string-name><surname>Peters</surname> <given-names>JL</given-names></string-name>, <string-name><surname>Sutton</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Jones</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Abrams</surname> <given-names>KR</given-names></string-name>, <string-name><surname>Rushton</surname> <given-names>L.</given-names></string-name> <article-title>Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry</article-title>. <source>J Clin Epidemiol</source> <year>2008</year>; <volume>61</volume>(<issue>10</issue>): <fpage>991</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c56"><label>56.</label><mixed-citation publication-type="journal"><string-name><surname>Guyatt</surname> <given-names>GH</given-names></string-name>, <string-name><surname>Oxman</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Vist</surname> <given-names>GE</given-names></string-name>, <etal>et al.</etal> <article-title>GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</article-title>. <source>BMJ</source> <year>2008</year>; <volume>336</volume>(<issue>7650</issue>): <fpage>924</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="c57"><label>57.</label><mixed-citation publication-type="journal"><string-name><surname>Egger</surname> <given-names>M</given-names></string-name>, <string-name><surname>Davey Smith</surname> <given-names>G</given-names></string-name>, <string-name><surname>Schneider</surname> <given-names>M</given-names></string-name>, <string-name><surname>Minder</surname> <given-names>C.</given-names></string-name> <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source> <year>1997</year>; <volume>315</volume>(<issue>7109</issue>): <fpage>629</fpage>&#x2013;<lpage>34</lpage>.</mixed-citation></ref>
<ref id="c58"><label>58.</label><mixed-citation publication-type="journal"><string-name><surname>Sterne</surname> <given-names>JA</given-names></string-name>, <string-name><surname>Sutton</surname> <given-names>AJ</given-names></string-name>, <string-name><surname>Ioannidis</surname> <given-names>JP</given-names></string-name>, <etal>et al.</etal> <article-title>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</article-title>. <source>BMJ</source> <year>2011</year>; <volume>343</volume>: <fpage>d4002</fpage>.</mixed-citation></ref>
<ref id="c59"><label>59.</label><mixed-citation publication-type="journal"><string-name><surname>Kantor</surname> <given-names>ED</given-names></string-name>, <string-name><surname>Rehm CD</surname>, <given-names>D. M</given-names></string-name>, <string-name><surname>White</surname> <given-names>E</given-names></string-name>, <string-name><surname>Giovannucci</surname> <given-names>EL</given-names></string-name>. <article-title>Trends in Dietary Supplement Use Among US Adults From 1999-2012</article-title>. <source>JAMA</source> <year>2016</year>; <volume>316</volume>(<issue>14</issue>): <fpage>1464</fpage>&#x2013;<lpage>74</lpage>.</mixed-citation></ref>
<ref id="c60"><label>60.</label><mixed-citation publication-type="journal"><string-name><surname>Jetter</surname> <given-names>A</given-names></string-name>, <string-name><surname>Egli</surname> <given-names>A</given-names></string-name>, <string-name><surname>Dawson-Hughes</surname> <given-names>B</given-names></string-name>, <etal>et al.</etal> <article-title>Pharmacokinetics of oral vitamin D(3) and calcifediol</article-title>. <source>Bone</source> <year>2014</year>; <volume>59</volume>: <fpage>14</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
</ref-list>
<sec id="s9">
<title>Supplementary Material</title>
<sec id="s9a">
<title>Methods</title>
<p>Search Strategies</p>
<p>A. Medline</p>
<sec id="s9a1">
<title>Cochrane Highly Sensitive Search Strategy for identifying randomised controlled trials</title>
<p>#1. randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]</p>
<p>#2. animals [mh] NOT humans [mh]</p>
<p>#3. #1 NOT #2</p>
</sec>
<sec id="s9a2">
<title>Terms specific to vitamin D</title>
<p>#4. Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol</p>
</sec>
<sec id="s9a3">
<title>Terms specific to acute respiratory infection</title>
<p>#5. Acute Respiratory Infection OR Upper Respiratory Infection OR Lower Respiratory Infection OR Respiratory Tract Infection OR Common Cold OR Sinusitis OR Pharyngitis OR Laryngitis OR Laryngotracheobronchitis OR Tonsillitis OR peritonsillar abscess OR Croup OR Epiglottitis OR supraglottitis OR Otitis Media OR Pneumonia OR Bronchopneumonia OR Bronchitis OR Pleurisy OR Pleuritis</p>
</sec>
<sec id="s9a4">
<title>Combination of terms to identify randomised controlled trials of vitamin D for the prevention of acute respiratory infection</title>
<p>#3 AND #4 AND #5</p>
<p>B. EMBASE</p>
</sec>
<sec id="s9a5">
<title>Terms for identifying randomised controlled trials</title>
<p>#1 &#x2018;randomized controlled trial&#x2019;/exp OR &#x2018;single blind procedure&#x2019;/exp OR &#x2018;double blind procedure&#x2019;/exp OR &#x2018;crossover procedure&#x2019;/exp</p>
<p>#2 random&#x002A;:ab,ti OR placebo&#x002A;:ab,ti OR crossover&#x002A;:ab,ti OR &#x2018;cross over&#x2019;:ab,ti OR allocat&#x002A;:ab,ti OR ((singl&#x002A; OR doubl&#x002A;) NEXT/1 blind&#x002A;):ab,ti OR trial:ti</p>
<p>#3. #1 OR #2</p>
</sec>
<sec id="s9a6">
<title>Terms specific to vitamin D</title>
<p>#4. vitamin AND d OR vitamin AND d2 OR vitamin AND d3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol</p>
</sec>
<sec id="s9a7">
<title>Terms specific to acute respiratory infection</title>
<p>#5. acute AND respiratory AND infection OR upper AND respiratory AND infection OR lower AND respiratory AND infection OR respiratory AND tract AND infection OR common AND cold OR sinusitis OR pharyngitis OR laryngitis OR laryngotracheobronchitis OR tonsillitis OR peritonsillar AND abscess OR croup OR epiglottitis OR supraglottitis OR otitis AND media OR pneumonia OR bronchopneumonia OR bronchitis OR pleurisy OR pleuritis</p>
</sec>
<sec id="s9a8">
<title>Combination of terms to identify randomised controlled trials of vitamin D for the prevention of acute respiratory infection</title>
<p>#3 AND #4 AND #5</p>
<p>C. Cochrane Central</p>
</sec>
<sec id="s9a9">
<title>Terms specific to vitamin D</title>
<p>#1. Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol</p>
</sec>
<sec id="s9a10">
<title>Terms specific to acute respiratory infection</title>
<p>#2. Acute Respiratory Infection OR Upper Respiratory Infection OR Lower Respiratory Infection OR Respiratory Tract Infection OR Common Cold OR Sinusitis OR Pharyngitis OR Laryngitis OR Laryngotracheobronchitis OR Tonsillitis OR peritonsillar abscess OR Croup OR Epiglottitis OR supraglottitis OR Otitis Media OR Pneumonia OR Bronchopneumonia OR Bronchitis OR Pleurisy OR Pleuritis</p>
</sec>
<sec id="s9a11">
<title>Combination of terms to identify randomised controlled trials of vitamin D for the prevention of acute respiratory infection</title>
<p>#1 AND #2</p>
<p>D. Web of Science</p>
<p>TS =(Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol) AND TS =(Acute Respiratory Infection OR Upper Respiratory Infection OR Lower Respiratory Infection OR Respiratory Tract Infection OR Common Cold OR Sinusitis OR Pharyngitis OR Laryngitis OR Laryngotracheobronchitis OR Tonsillitis OR peritonsillar abscess OR Croup OR Epiglottitis OR supraglottitis OR Otitis Media OR Pneumonia OR Bronchopneumonia OR Bronchitis OR Pleurisy OR Pleuritis) AND TS =(placebo&#x002A; or random&#x002A; or clinical trial&#x002A; or double blind&#x002A; or single blind&#x002A; or rct)</p>
<p>E. ClinicalTrials.gov</p>
<p>Vitamin D AND respiratory AND infection</p>
</sec>
<sec id="s9a12">
<title>Sources of support for participating trials</title>
<p>The trial by Aglipay and colleagues was supported by the competitive grants from the Canadian Institutes of Health Research Institutes of Human Development, Child and Youth Health and Nutrition, Metabolism and Diabetes (grant number MOP-114945) and the Thrasher Research Fund (award number 9113).</p>
<p>The trial by Aloia and colleagues was supported by the National Institute of Aging (grant number R01-AG032440-01A2).</p>
<p>The trial by Arihiro and colleagues was supported by the Ministry of Education, Culture, Sports, Science, and Technology in the Japan-Supported Program for the Strategic Research Foundation at Private Universities and funding from the Department of Gastroenterology and Hepatology, Jikei University of Medicine, Tokyo, Japan.</p>
<p>The trial by Bergman et al was supported by grants from the Swedish Research Council, the Strategic Research Foundation (SSF), the Swedish Heart and Lung foundation, Karolinska Institutet, Stockholm County Council and the Swedish Cancer Society as well as by the Magnus Bergwall and &#x00C5;ke Wiberg foundations.</p>
<p>The trials by Camargo and colleagues were supported by a grant for the Blue Sky Study from an anonymous foundation and the Massachusetts General Hospital; and the Health Research Council of New Zealand (grant number 10/400) and the Accident Compensation Corporation of New Zealand.</p>
<p>The trial by Ganmaa and colleagues was supported by the National Institutes of Health (Grant Number 1R01HL122624-01).</p>
<p>The trial by Ginde and colleagues was supported by NIH/NIA grant K23AG040708, NIH/NCATS Colorado CTSA Grant UL1TR001082, and the American Geriatrics Society Jahnigen Career Development Scholars Award.</p>
<p>The trial by Golan-Tripto and colleagues was supported by the Soroka JNF UK Clinical Research Scholar Program.</p>
<p>The trial by Goodall and colleagues was supported in part by the Canadian Institutes of Health Research [OPP 86940] and with in-kind support from Copan Italia, Bresica Italy.</p>
<p>The trial by Grant and colleagues was supported by the Health Research Council of New Zealand, Grant Number 09/215R.</p>
<p>The trial by Gupta and colleagues was supported by the Indian Council of Medical Research, New Delhi.</p>
<p>The trial by Hauger and colleagues was supported by Lundbeckfonden (grant number R180-2014-3481), by Br&#x00F8;drene Hartmann&#x2019;s Fund (A26842), and by the European</p>
<p>Commission (FP7/2007&#x2013;2013) under Grant Agreement 613977 for the ODIN Integrated Project (Food-based solutions for optimal vitamin D nutrition and health through the life cycle).</p>
<p>The trial by Hibbs and colleagues was supported by the National Heart, Lung, and Blood Institute and Office of Dietary Supplements (grant number R01HL109293).</p>
<p>The trial by Lee and colleagues was supported by the US Food and Drug Administration Orphan Product Development (grant number R01FD003894).</p>
<p>The trial by Loeb and colleagues was supported by the Institute for Infectious Diseases Research at McMaster University.</p>
<p>The trials by Manaseki-Holland and colleagues were supported by New Zealand Aid (ref: GRA/470/2) and The Wellcome Trust (ref: 082476).</p>
<p>The trial by Mandlik and colleagues was supported by a core grant from the Hirabai Cowasji Jehangir Medical Research Institute.</p>
<p>The trials by Martineau and colleagues were supported by the National Institute for Health Research under its Programme Grants for Applied Research Programme (Reference Number RP-PG-0407-10398).</p>
<p>The trial by Murdoch and colleagues was supported by the Health Research Council of New Zealand, grant number 09/302.</p>
<p>The trial by Pham and colleagues was supported by project grants from the National Health and Medical Research Council (grant numbers GNT1046681 and GNT1120682).</p>
<p>The trial by Reyes and colleagues was supported by Fondo Nacional de Investigacion y Desarrollo en Salud (ref. SA13I20173).</p>
<p>The trial by Rosendahl and colleagues was supported by the Foundation for Pediatric Research, the Finnish Medical Foundation, Governmental Subsidy for Clinical Research, the P&#x00E4;ivikki and Sakari Sohlberg Foundation, the Academy of Finland, the Sigrid Jus&#x00E9;lius Foundation, the Folkh&#x00E4;lsan Research Foundation, the Novo Nordisk Foundation, the Orion Research Foundation, and Barncancerfonden.</p>
<p>The trial by Rake and colleagues was supported by the National Institute for Health Research Health Technology Assessment programme (ref. HTA 08/116/48).</p>
<p>The trial by Rees and colleagues was supported by the National Cancer Institute at the National Institutes of Health (grant numbers CA098286 and CA098286-S).</p>
<p>The trial by Shimizu and colleagues was supported by the FANCL Corporation.</p>
<p>The trial by Simpson and colleagues was supported by the Royal Hobart Hospital Research Foundation.</p>
<p>The trial by Tachimoto and colleagues was supported by the Ministry of Education, Culture, Sports, Science, and Technology in the Japan-Supported Program for the Strategic Research Foundation at Private Universities, JSPH KAKENHI Grant Number 23591553, and funding from Jikei University of Medicine, Tokyo, Japan.</p>
<p>The trial by Tran and colleagues was supported by the National Health and Medical Research Council of Australia, grant 613655.</p>
<p>The trial by Trilok Kumar and colleagues was supported by the Department of Biotechnology, Government of India (ref BT/PR-PR7489/PID/20/285/2006), Nutrition Third World and Sight and Life.</p>
<table-wrap id="tblS1" orientation="portrait" position="float">
<label>Table S1:</label>
<caption><title>Reasons for exclusion of potentially relevant studies</title></caption>
<graphic xlink:href="20152728v2_tblS1.tif"/>
</table-wrap>
<table-wrap id="tblS2" orientation="portrait" position="float">
<label>Table S2:</label>
<caption><p>Risk of Bias Assessment</p></caption>
<graphic xlink:href="20152728v2_tblS2.tif"/>
</table-wrap>
<table-wrap id="tblS3" orientation="portrait" position="float">
<label>Table S3:</label>
<caption><p>Multivariate meta-regression model for proportion of participants experiencing at least one acute respiratory tract infection, by trial-level subgroups.</p></caption>
<graphic xlink:href="20152728v2_tblS3.tif"/>
</table-wrap>
<table-wrap id="tblS4" orientation="portrait" position="float">
<label>Table S4:</label>
<caption><p>Summary of Findings Table</p></caption>
<graphic xlink:href="20152728v2_tblS4.tif"/>
</table-wrap>
<table-wrap id="tblS5" orientation="portrait" position="float">
<label>Table S5:</label>
<caption><p>Results of exploratory sensitivity analyses excluding placebo-controlled trials at unclear risk of bias and studies investigating ARI incidence as a secondary outcome.</p></caption>
<graphic xlink:href="20152728v2_tblS5.tif"/>
</table-wrap>
<fig id="figS1" position="float" fig-type="figure">
<label>Figure S1:</label>
<caption><p>Cates plot illustrating reduction in risk of one or more acute respiratory infections with vitamin D supplementation vs. placebo (primary comparison), <bold>A)</bold> Overall, and <bold>B)</bold> in trials with duration &#x2264;12 months where vitamin D<sub>3</sub> was administered using daily doses of 400-1000 IU/day.</p></caption>
<graphic xlink:href="20152728v2_figS1.tif"/>
</fig>
<fig id="figS2" position="float" fig-type="figure">
<label>Figure S2:</label>
<caption><p>Forest plot of RCTs comparing effects of higher-vs. lower-dose vitamin D, reporting proportion of participants experiencing at least one acute respiratory infection.</p>
<p>&#x002A;This analysis includes data from the subset of ViDiFlu trial participants who were randomised to higher-vs. lower-dose vitamin D.</p></caption>
<graphic xlink:href="20152728v2_figS2.tif"/>
</fig>
<fig id="figS3" position="float" fig-type="figure">
<label>Figure S3:</label>
<caption><p>Forest plot of RCTs comparing effects of vitamin D vs. placebo, reporting proportion of participants experiencing at least one acute respiratory infection, by baseline 25-hydroxyvitamin D level. <bold>A)</bold> &#x003C;25.0 nmol/L; <bold>B)</bold> 25.0 to 49.9 nmol/L; <bold>C)</bold> 50.0 to 74.9 nmol/L, and <bold>D)</bold> &#x2265;75.0 nmol/L.</p></caption>
<graphic xlink:href="20152728v2_figS3.tif"/>
</fig>
<fig id="figS4" position="float" fig-type="figure">
<label>Figure S4:</label>
<caption><p>Forest plot of RCTs comparing effects of vitamin D vs. placebo, reporting proportion of participants experiencing at least one acute respiratory infection, by frequency of supplementation (daily vs. weekly vs. monthly to 3-monthly)</p>
<p>&#x002A;This analysis includes data from the subset of ViDiFlu trial participants who were randomised to vitamin D vs. placebo control. &#x002A;&#x002A;For this trial, participants were asked to report the occurrence of ARTI during the one month prior to completing each annual survey (max surveys=5). The numerator is the number of people who reported an ARTI on at least one survey. The ARTI outcomes for people who completed fewer than 5 surveys and who did not report an ARTI (N=2239; 14%) were estimated based on the % affected among those who completed all 5 surveys (N=12,152; 76%).</p></caption>
<graphic xlink:href="20152728v2_figS4.tif"/>
</fig>
<fig id="figS5" position="float" fig-type="figure">
<label>Figure S5:</label>
<caption><p>Forest plot of RCTs comparing effects of vitamin D vs. placebo, reporting proportion of participants experiencing at least one acute respiratory infection, by daily dose equivalents (&#x003C;400 IU/day vs. 400-1000 IU/day vs. 1001-2000 IU/day vs. &#x003E;2000 IU/day).</p>
<p>&#x002A;This analysis includes data from the subset of ViDiFlu trial participants who were randomised to vitamin D vs. placebo control. &#x002A;&#x002A;For this trial, participants were asked to report the occurrence of ARTI during the one month prior to completing each annual survey (max surveys=5). The numerator is the number of people who reported an ARTI on at least one survey. The ARTI outcomes for people who completed fewer than 5 surveys and who did not report an ARTI (N=2239; 14%) were estimated based on the % affected among those who completed all 5 surveys (N=12,152; 76%).</p></caption>
<graphic xlink:href="20152728v2_figS5.tif"/>
</fig>
<fig id="figS6" position="float" fig-type="figure">
<label>Figure S6:</label>
<caption><p>Forest plot of RCTs comparing effects of vitamin D vs. placebo, reporting proportion of participants experiencing at least one acute respiratory infection, by trial duration (&#x2264;12 months vs. &#x003E;12 months).</p>
<p>&#x002A;This analysis includes data from the subset of ViDiFlu trial participants who were randomised to vitamin D vs. placebo control. &#x002A;&#x002A;For this trial, participants were asked to report the occurrence of ARTI during the one month prior to completing each annual survey (max surveys=5). The numerator is the number of people who reported an ARTI on at least one survey. The ARTI outcomes for people who completed fewer than 5 surveys and who did not report an ARTI (N=2239; 14%) were estimated based on the % affected among those who completed all 5 surveys (N=12,152; 76%).</p></caption>
<graphic xlink:href="20152728v2_figS6.tif"/>
</fig>
<fig id="figS7" position="float" fig-type="figure">
<label>Figure S7:</label>
<caption><p>Forest plot of RCTs comparing effects of vitamin D vs. placebo, reporting proportion of participants experiencing at least one acute respiratory infection, by the following age strata: <bold>A)</bold> &#x003C;1 year; <bold>B)</bold> 1-15.99 years; <bold>C)</bold> 16-64.99 years, and <bold>D)</bold> &#x2265;65 years</p>
<p>&#x002A;This analysis includes data from the subset of ViDiFlu trial participants who were randomised to vitamin D vs. placebo control. &#x002A;&#x002A;For this trial, participants were asked to report the occurrence of ARTI during the one month prior to completing each annual survey (max surveys=5). The numerator is the number of people who reported an ARTI on at least one survey. The ARTI outcomes for people who completed fewer than 5 surveys and who did not report an ARTI (N=2239; 14%) were estimated based on the % affected among those who completed all 5 surveys (N=12,152; 76%).</p></caption>
<graphic xlink:href="20152728v2_figS7.tif"/>
</fig>
<fig id="figS8" position="float" fig-type="figure">
<label>Figure S8:</label>
<caption><p>Forest plot of RCTs comparing effects of vitamin D vs. placebo, reporting proportion of participants experiencing at least one acute respiratory infection, by presence or absence of airway disease comorbidity.</p>
<p>&#x002A;This analysis includes data from the subset of ViDiFlu trial participants who were randomised to vitamin D vs. placebo control. &#x002A;&#x002A;For this trial, participants were asked to report the occurrence of ARTI during the one month prior to completing each annual survey (max surveys=5). The numerator is the number of people who reported an ARTI on at least one survey. The ARTI outcomes for people who completed fewer than 5 surveys and who did not report an ARTI (N=2239; 14%) were estimated based on the % affected among those who completed all 5 surveys (N=12,152; 76%).</p></caption>
<graphic xlink:href="20152728v2_figS8.tif"/>
</fig>
<fig id="figS9" position="float" fig-type="figure">
<label>Figure S9.</label>
<caption><p>Forest plot of sub-set of RCTs with duration &#x2264;12 months comparing effects of daily vitamin D at a dose of 400-1000 IU/day vs. placebo, reporting proportion of participants experiencing at least one acute respiratory infection</p></caption>
<graphic xlink:href="20152728v2_figS9.tif"/>
</fig>
<fig id="figS10" position="float" fig-type="figure">
<label>Figure S10:</label>
<caption><p>Funnel plot of placebo-controlled RCTs reporting proportion of participants experiencing 1 or more acute respiratory infection.</p>
<p>Egger&#x2019;s test for publication bias: P=0.008</p></caption>
<graphic xlink:href="20152728v2_figS10.tif"/>
</fig>
</sec>
</sec>
</sec>
<ref-list>
<title>References</title>
<ref id="sc1"><label>1.</label><mixed-citation publication-type="journal"><string-name><surname>Somnath</surname> <given-names>SH</given-names></string-name>, <string-name><surname>Biswal</surname> <given-names>N</given-names></string-name>, <string-name><surname>Chandrasekaran</surname> <given-names>V</given-names></string-name>, <string-name><surname>Jagadisan</surname> <given-names>B</given-names></string-name>, <string-name><surname>Bobby</surname> <given-names>Z.</given-names></string-name> <article-title>Therapeutic effect of vitamin D in acute lower respiratory infection: A randomized controlled trial</article-title>. <source>Clin Nutr ESPEN</source> <year>2017</year>; <volume>20</volume>: <fpage>24</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="sc2"><label>2.</label><mixed-citation publication-type="journal"><string-name><surname>Jung</surname> <given-names>HC</given-names></string-name>, <string-name><surname>Seo</surname> <given-names>M-W</given-names></string-name>, <string-name><surname>Lee</surname> <given-names>S</given-names></string-name>, <string-name><surname>Kim</surname> <given-names>SW</given-names></string-name>, <string-name><surname>Song</surname> <given-names>JK</given-names></string-name>. <article-title>Vitamin D<sub>3</sub> Supplementation Reduces the Symptoms of Upper Respiratory Tract Infection during Winter Training in Vitamin D-Insufficient Taekwondo Athletes: A Randomized Controlled Trial</article-title>. <source>Int J Environ Res Public Health</source> <year>2018</year>; <volume>15</volume>(<issue>9</issue>): <fpage>2003</fpage>.</mixed-citation></ref>
<ref id="sc3"><label>3.</label><mixed-citation publication-type="journal"><string-name><surname>Ramos-Martinez</surname> <given-names>E</given-names></string-name>, <string-name><surname>Lopez-Vancell</surname> <given-names>MR</given-names></string-name>, <string-name><surname>Fernandez de Cordova-Aguirre</surname> <given-names>JC</given-names></string-name>, <etal>et al.</etal> <article-title>Reduction of respiratory infections in asthma patients supplemented with vitamin D is related to increased serum IL-10 and IFNgamma levels and cathelicidin expression</article-title>. <source>Cytokine</source> <year>2018</year>; <volume>108</volume>: <fpage>239</fpage>&#x2013;<lpage>46</lpage>.</mixed-citation></ref>
<ref id="sc4"><label>4.</label><mixed-citation publication-type="journal"><string-name><surname>Zhou</surname> <given-names>J</given-names></string-name>, <string-name><surname>Du</surname> <given-names>J</given-names></string-name>, <string-name><surname>Huang</surname> <given-names>L</given-names></string-name>, <string-name><surname>Wang</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Shi</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Lin</surname> <given-names>H.</given-names></string-name> <article-title>Preventive Effects of Vitamin D on Seasonal Influenza A in Infants: A Multicenter, Randomized, Open, Controlled Clinical Trial</article-title>. <source>The Pediatric Infectious Disease Journal</source> <year>2018</year>; <volume>37</volume>(<issue>8</issue>): <fpage>749</fpage>&#x2013;<lpage>54</lpage>.</mixed-citation></ref>
<ref id="sc5"><label>5.</label><mixed-citation publication-type="journal"><string-name><surname>Hueniken</surname> <given-names>K</given-names></string-name>, <string-name><surname>Aglipay</surname> <given-names>M</given-names></string-name>, <string-name><surname>Birken</surname> <given-names>CS</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of High-Dose Vitamin D Supplementation on Upper Respiratory Tract Infection Symptom Severity in Healthy Children</article-title>. <source>Pediatr Infect Dis J</source> <year>2019</year>; <volume>38</volume>(<issue>6</issue>): <fpage>564</fpage>&#x2013;<lpage>8</lpage>.</mixed-citation></ref>
<ref id="sc6"><label>6.</label><mixed-citation publication-type="journal"><string-name><surname>Aglipay</surname> <given-names>M</given-names></string-name>, <string-name><surname>Birken</surname> <given-names>CS</given-names></string-name>, <string-name><surname>Parkin</surname> <given-names>PC</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children</article-title>. <source>JAMA</source> <year>2017</year>; <volume>318</volume>(<issue>3</issue>): <fpage>245</fpage>&#x2013;<lpage>54</lpage>.</mixed-citation></ref>
<ref id="sc7"><label>7.</label><mixed-citation publication-type="journal"><string-name><surname>Singh</surname> <given-names>N</given-names></string-name>, <string-name><surname>Kamble</surname> <given-names>D</given-names></string-name>, <string-name><surname>Mahantshetti</surname> <given-names>NS</given-names></string-name>. <article-title>Effect of Vitamin D Supplementation in the Prevention of Recurrent Pneumonia in Under-Five Children</article-title>. <source>Indian Journal of Pediatrics</source> <year>2019</year>; <volume>86</volume>(<issue>12</issue>): <fpage>1105</fpage>&#x2013;<lpage>11</lpage>.</mixed-citation></ref>
<ref id="sc8"><label>8.</label><mixed-citation publication-type="journal"><string-name><surname>Li-Ng</surname> <given-names>M</given-names></string-name>, <string-name><surname>Aloia</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Pollack</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>A randomized controlled trial of vitamin D3 supplementation for the prevention of symptomatic upper respiratory tract infections</article-title>. <source>Epidemiol Infect</source> <year>2009</year>; <volume>137</volume>(<issue>10</issue>): <fpage>1396</fpage>&#x2013;<lpage>404</lpage>.</mixed-citation></ref>
<ref id="sc9"><label>9.</label><mixed-citation publication-type="journal"><string-name><surname>Urashima</surname> <given-names>M</given-names></string-name>, <string-name><surname>Segawa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Okazaki</surname> <given-names>M</given-names></string-name>, <string-name><surname>Kurihara</surname> <given-names>M</given-names></string-name>, <string-name><surname>Wada</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ida</surname> <given-names>H.</given-names></string-name> <article-title>Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren</article-title>. <source>Am J Clin Nutr</source> <year>2010</year>; <volume>91</volume>(<issue>5</issue>): <fpage>1255</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="sc10"><label>10.</label><mixed-citation publication-type="journal"><string-name><surname>Manaseki-Holland</surname> <given-names>S</given-names></string-name>, <string-name><surname>Qader</surname> <given-names>G</given-names></string-name>, <string-name><surname>Isaq Masher</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial</article-title>. <source>Trop Med Int Health</source> <year>2010</year>; <volume>15</volume>(<issue>10</issue>): <fpage>1148</fpage>&#x2013;<lpage>55</lpage>.</mixed-citation></ref>
<ref id="sc11"><label>11.</label><mixed-citation publication-type="journal"><string-name><surname>Laaksi</surname> <given-names>I</given-names></string-name>, <string-name><surname>Ruohola</surname> <given-names>JP</given-names></string-name>, <string-name><surname>Mattila</surname> <given-names>V</given-names></string-name>, <string-name><surname>Auvinen</surname> <given-names>A</given-names></string-name>, <string-name><surname>Ylikomi</surname> <given-names>T</given-names></string-name>, <string-name><surname>Pihlajamaki</surname> <given-names>H.</given-names></string-name> <article-title>Vitamin D supplementation for the prevention of acute respiratory tract infection: a randomized, double-blinded trial among young Finnish men</article-title>. <source>J Infect Dis</source> <year>2010</year>; <volume>202</volume>(<issue>5</issue>): <fpage>809</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="sc12"><label>12.</label><mixed-citation publication-type="journal"><string-name><surname>Majak</surname> <given-names>P</given-names></string-name>, <string-name><surname>Olszowiec-Chlebna</surname> <given-names>M</given-names></string-name>, <string-name><surname>Smejda</surname> <given-names>K</given-names></string-name>, <string-name><surname>Stelmach</surname> <given-names>I.</given-names></string-name> <article-title>Vitamin D supplementation in children may prevent asthma exacerbation triggered by acute respiratory infection</article-title>. <source>J Allergy Clin Immunol</source> <year>2011</year>; <volume>127</volume>(<issue>5</issue>): <fpage>1294</fpage>&#x2013;<lpage>6</lpage>.</mixed-citation></ref>
<ref id="sc13"><label>13.</label><mixed-citation publication-type="journal"><string-name><surname>Kumar</surname> <given-names>GT</given-names></string-name>, <string-name><surname>Sachdev</surname> <given-names>HS</given-names></string-name>, <string-name><surname>Chellani</surname> <given-names>H</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of weekly vitamin D supplements on mortality, morbidity, and growth of low birthweight term infants in India up to age 6 months: randomised controlled trial</article-title>. <source>BMJ</source> <year>2011</year>; <volume>342</volume>: <fpage>d2975</fpage>.</mixed-citation></ref>
<ref id="sc14"><label>14.</label><mixed-citation publication-type="journal"><string-name><surname>Lehouck</surname> <given-names>A</given-names></string-name>, <string-name><surname>Mathieu</surname> <given-names>C</given-names></string-name>, <string-name><surname>Carremans</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>High doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trial</article-title>. <source>Ann Intern Med</source> <year>2012</year>; <volume>156</volume>(<issue>2</issue>): <fpage>105</fpage>&#x2013;<lpage>14</lpage>.</mixed-citation></ref>
<ref id="sc15"><label>15.</label><mixed-citation publication-type="journal"><string-name><surname>Manaseki-Holland</surname> <given-names>S</given-names></string-name>, <string-name><surname>Maroof</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Bruce</surname> <given-names>J</given-names></string-name>, <etal>et al.</etal> <article-title>Effect on the incidence of pneumonia of vitamin D supplementation by quarterly bolus dose to infants in Kabul: a randomised controlled superiority trial</article-title>. <source>Lancet</source> <year>2012</year>; <volume>379</volume>(<issue>9824</issue>): <fpage>1419</fpage>&#x2013;<lpage>27</lpage>.</mixed-citation></ref>
<ref id="sc16"><label>16.</label><mixed-citation publication-type="journal"><string-name><surname>Camargo</surname> <given-names>CA</given-names>, <suffix>Jr.</suffix></string-name>, <string-name><surname>Ganmaa</surname> <given-names>D</given-names></string-name>, <string-name><surname>Frazier</surname> <given-names>AL</given-names></string-name>, <etal>et al.</etal> <article-title>Randomized trial of vitamin D supplementation and risk of acute respiratory infection in Mongolia</article-title>. <source>Pediatrics</source> <year>2012</year>; <volume>130</volume>(<issue>3</issue>): <fpage>e561</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="sc17"><label>17.</label><mixed-citation publication-type="journal"><string-name><surname>Murdoch</surname> <given-names>DR</given-names></string-name>, <string-name><surname>Slow</surname> <given-names>S</given-names></string-name>, <string-name><surname>Chambers</surname> <given-names>ST</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of vitamin D3 supplementation on upper respiratory tract infections in healthy adults: the VIDARIS randomized controlled trial</article-title>. <source>JAMA</source> <year>2012</year>; <volume>308</volume>(<issue>13</issue>): <fpage>1333</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="sc18"><label>18.</label><mixed-citation publication-type="journal"><string-name><surname>Bergman</surname> <given-names>P</given-names></string-name>, <string-name><surname>Norlin</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Hansen</surname> <given-names>S</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study</article-title>. <source>BMJ Open</source> <year>2012</year>; <volume>2</volume>(<issue>6</issue>): <fpage>e001663</fpage>.</mixed-citation></ref>
<ref id="sc19"><label>19.</label><mixed-citation publication-type="journal"><string-name><surname>Marchisio</surname> <given-names>P</given-names></string-name>, <string-name><surname>Consonni</surname> <given-names>D</given-names></string-name>, <string-name><surname>Baggi</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D supplementation reduces the risk of acute otitis media in otitis-prone children</article-title>. <source>Pediatr Infect Dis J</source> <year>2013</year>; <volume>32</volume>(<issue>10</issue>): <fpage>1055</fpage>&#x2013;<lpage>60</lpage>.</mixed-citation></ref>
<ref id="sc20"><label>20.</label><mixed-citation publication-type="other"><string-name><surname>Rees</surname> <given-names>JR</given-names></string-name>, <string-name><surname>Hendricks</surname> <given-names>K</given-names></string-name>, <string-name><surname>Barry</surname> <given-names>EL</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D3 Supplementation and Upper Respiratory Tract Infections in a Randomized, Controlled Trial</article-title>. <source>Clin Infect Dis</source> <year>2013</year>.</mixed-citation></ref>
<ref id="sc21"><label>21.</label><mixed-citation publication-type="journal"><string-name><surname>Tran</surname> <given-names>B</given-names></string-name>, <string-name><surname>Armstrong</surname> <given-names>BK</given-names></string-name>, <string-name><surname>Ebeling</surname> <given-names>PR</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of vitamin D supplementation on antibiotic use: a randomized controlled trial</article-title>. <source>Am J Clin Nutr</source> <year>2014</year>; <volume>99</volume>(<issue>1</issue>): <fpage>156</fpage>&#x2013;<lpage>61</lpage>.</mixed-citation></ref>
<ref id="sc22"><label>22.</label><mixed-citation publication-type="journal"><string-name><surname>Goodall</surname> <given-names>EC</given-names></string-name>, <string-name><surname>Granados</surname> <given-names>AC</given-names></string-name>, <string-name><surname>Luinstra</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D3 and gargling for the prevention of upper respiratory tract infections: a randomized controlled trial</article-title>. <source>BMC Infectious Diseases</source> <year>2014</year>; <volume>14</volume>: <fpage>273</fpage>.</mixed-citation></ref>
<ref id="sc23"><label>23.</label><mixed-citation publication-type="journal"><string-name><surname>Urashima</surname> <given-names>M</given-names></string-name>, <string-name><surname>Mezawa</surname> <given-names>H</given-names></string-name>, <string-name><surname>Noya</surname> <given-names>M</given-names></string-name>, <string-name><surname>Camargo</surname> <given-names>CA</given-names>, <suffix>Jr.</suffix></string-name> <article-title>Effects of vitamin D supplements on influenza A illness during the 2009 H1N1 pandemic: a randomized controlled trial</article-title>. <source>Food &#x0026; Function</source> <year>2014</year>; <volume>5</volume>(<issue>9</issue>): <fpage>2365</fpage>&#x2013;<lpage>70</lpage>.</mixed-citation></ref>
<ref id="sc24"><label>24.</label><mixed-citation publication-type="other"><string-name><surname>Grant</surname> <given-names>CC</given-names></string-name>, <string-name><surname>Kaur</surname> <given-names>S</given-names></string-name>, <string-name><surname>Waymouth</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Reduced primary care respiratory infection visits following pregnancy and infancy vitamin D supplementation: a randomised controlled trial</article-title>. <source>Acta Paediatr</source> <year>2014</year>.</mixed-citation></ref>
<ref id="sc25"><label>25.</label><mixed-citation publication-type="journal"><string-name><surname>Martineau</surname> <given-names>AR</given-names></string-name>, <string-name><surname>James</surname> <given-names>WY</given-names></string-name>, <string-name><surname>Hooper</surname> <given-names>RL</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trial</article-title>. <source>The Lancet Respiratory Medicine</source> <year>2015</year>; <volume>3</volume>(<issue>2</issue>): <fpage>120</fpage>&#x2013;<lpage>30</lpage>.</mixed-citation></ref>
<ref id="sc26"><label>26.</label><mixed-citation publication-type="journal"><string-name><surname>Martineau</surname> <given-names>AR</given-names></string-name>, <string-name><surname>MacLaughlin</surname> <given-names>BD</given-names></string-name>, <string-name><surname>Hooper</surname> <given-names>RL</given-names></string-name>, <etal>et al.</etal> <article-title>Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs)</article-title>. <source>Thorax</source> <year>2015</year>; <volume>70</volume>(<issue>5</issue>): <fpage>451</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="sc27"><label>27.</label><mixed-citation publication-type="other"><string-name><surname>Martineau</surname> <given-names>AR</given-names></string-name>, <string-name><surname>Hanifa</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Witt</surname> <given-names>KD</given-names></string-name>, <etal>et al.</etal> <article-title>Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu)</article-title>. <source>Thorax</source> <year>2015</year>.</mixed-citation></ref>
<ref id="sc28"><label>28.</label><mixed-citation publication-type="journal"><string-name><surname>Simpson</surname> <given-names>SJ</given-names></string-name>, <string-name><surname>van der Mei</surname> <given-names>I</given-names></string-name>, <string-name><surname>Stewart</surname> <given-names>N</given-names></string-name>, <string-name><surname>Blizzard</surname> <given-names>L</given-names></string-name>, <string-name><surname>Tettey</surname> <given-names>P</given-names></string-name>, <string-name><surname>Taylor</surname> <given-names>B.</given-names></string-name> <article-title>Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT</article-title>. <source>BMC Nutrition</source> <year>2015</year>; <volume>1</volume>(<issue>7</issue>).</mixed-citation></ref>
<ref id="sc29"><label>29.</label><mixed-citation publication-type="journal"><string-name><surname>Dubnov-Raz</surname> <given-names>G</given-names></string-name>, <string-name><surname>Rinat</surname> <given-names>B</given-names></string-name>, <string-name><surname>Hemila</surname> <given-names>H</given-names></string-name>, <string-name><surname>Choleva</surname> <given-names>L</given-names></string-name>, <string-name><surname>Cohen</surname> <given-names>AH</given-names></string-name>, <string-name><surname>Constantini</surname> <given-names>NW</given-names></string-name>. <article-title>Vitamin D supplementation and upper respiratory tract infections in adolescent swimmers: a randomized controlled trial</article-title>. <source>Pediatric Exercise Science</source> <year>2015</year>; <volume>27</volume>(<issue>1</issue>): <fpage>113</fpage>&#x2013;<lpage>9</lpage>.</mixed-citation></ref>
<ref id="sc30"><label>30.</label><mixed-citation publication-type="journal"><string-name><surname>Denlinger</surname> <given-names>LC</given-names></string-name>, <string-name><surname>King</surname> <given-names>TS</given-names></string-name>, <string-name><surname>Cardet</surname> <given-names>JC</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D Supplementation and the Risk of Colds in Patients with Asthma</article-title>. <source>Am J Respir Crit Care Med</source> <year>2016</year>; <volume>193</volume>(<issue>6</issue>): <fpage>634</fpage>&#x2013;<lpage>41</lpage>.</mixed-citation></ref>
<ref id="sc31"><label>31.</label><mixed-citation publication-type="other"><string-name><surname>Tachimoto</surname> <given-names>H</given-names></string-name>, <string-name><surname>Mezawa</surname> <given-names>H</given-names></string-name>, <string-name><surname>Segawa</surname> <given-names>T</given-names></string-name>, <string-name><surname>Akiyama</surname> <given-names>N</given-names></string-name>, <string-name><surname>Ida</surname> <given-names>H</given-names></string-name>, <string-name><surname>Urashima</surname> <given-names>M.</given-names></string-name> <article-title>Improved Control of Childhood Asthma with Low-Dose, Short-Term Vitamin D Supplementation: A Randomized, Double-Blind, Placebo-Controlled Trial</article-title>. <source>Allergy</source> <year>2016</year>.</mixed-citation></ref>
<ref id="sc32"><label>32.</label><mixed-citation publication-type="journal"><string-name><surname>Ginde</surname> <given-names>AA</given-names></string-name>, <string-name><surname>Blatchford</surname> <given-names>P</given-names></string-name>, <string-name><surname>Breese</surname> <given-names>K</given-names></string-name>, <etal>et al.</etal> <article-title>High-Dose Monthly Vitamin D for Prevention of Acute Respiratory Infection in Older Long-Term Care Residents: A Randomized Clinical Trial</article-title>. <source>J Am Geriatr Soc</source> <year>2017</year>; <volume>65</volume>(<issue>3</issue>): <fpage>496</fpage>&#x2013;<lpage>503</lpage>.</mixed-citation></ref>
<ref id="sc33"><label>33.</label><mixed-citation publication-type="journal"><string-name><surname>Gupta</surname> <given-names>P</given-names></string-name>, <string-name><surname>Dewan</surname> <given-names>P</given-names></string-name>, <string-name><surname>Shah</surname> <given-names>D</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D Supplementation for Treatment and Prevention of Pneumonia in Under-five Children: A Randomized Double-blind Placebo Controlled Trial</article-title>. <source>Indian Pediatr</source> <year>2016</year>; <volume>53</volume>(<issue>11</issue>): <fpage>967</fpage>&#x2013;<lpage>76</lpage>.</mixed-citation></ref>
<ref id="sc34"><label>34.</label><mixed-citation publication-type="journal"><string-name><surname>Arihiro</surname> <given-names>S</given-names></string-name>, <string-name><surname>Nakashima</surname> <given-names>A</given-names></string-name>, <string-name><surname>Matsuoka</surname> <given-names>M</given-names></string-name>, <etal>et al.</etal> <article-title>Randomized Trial of Vitamin D Supplementation to Prevent Seasonal Influenza and Upper Respiratory Infection in Patients With Inflammatory Bowel Disease</article-title>. <source>Inflamm Bowel Dis</source> <year>2019</year>; <volume>25</volume>(<issue>6</issue>): <fpage>1088</fpage>&#x2013;<lpage>95</lpage>.</mixed-citation></ref>
<ref id="sc35"><label>35.</label><mixed-citation publication-type="journal"><string-name><surname>Hibbs</surname> <given-names>AM</given-names></string-name>, <string-name><surname>Ross</surname> <given-names>K</given-names></string-name>, <string-name><surname>Kerns</surname> <given-names>LA</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of Vitamin D Supplementation on Recurrent Wheezing in Black Infants Who Were Born Preterm: The D-Wheeze Randomized Clinical Trial</article-title>. <source>JAMA</source> <year>2018</year>; <volume>319</volume>(<issue>20</issue>): <fpage>2086</fpage>&#x2013;<lpage>94</lpage>.</mixed-citation></ref>
<ref id="sc36"><label>36.</label><mixed-citation publication-type="journal"><string-name><surname>Lee</surname> <given-names>MT</given-names></string-name>, <string-name><surname>Kattan</surname> <given-names>M</given-names></string-name>, <string-name><surname>Fennoy</surname> <given-names>I</given-names></string-name>, <etal>et al.</etal> <article-title>Randomized phase 2 trial of monthly vitamin D to prevent respiratory complications in children with sickle cell disease</article-title>. <source>Blood Adv</source> <year>2018</year>; <volume>2</volume>(<issue>9</issue>): <fpage>969</fpage>&#x2013;<lpage>78</lpage>.</mixed-citation></ref>
<ref id="sc37"><label>37.</label><mixed-citation publication-type="journal"><string-name><surname>Loeb</surname> <given-names>M</given-names></string-name>, <string-name><surname>Dang</surname> <given-names>AD</given-names></string-name>, <string-name><surname>Thiem</surname> <given-names>VD</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of Vitamin D supplementation to reduce respiratory infections in children and adolescents in Vietnam: A randomized controlled trial</article-title>. <source>Influenza Other Respir Viruses</source> <year>2019</year>; <volume>13</volume>(<issue>2</issue>): <fpage>176</fpage>&#x2013;<lpage>83</lpage>.</mixed-citation></ref>
<ref id="sc38"><label>38.</label><mixed-citation publication-type="journal"><string-name><surname>Rosendahl</surname> <given-names>J</given-names></string-name>, <string-name><surname>Valkama</surname> <given-names>S</given-names></string-name>, <string-name><surname>Holmlund-Suila</surname> <given-names>E</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of Higher vs Standard Dosage of Vitamin D3 Supplementation on Bone Strength and Infection in Healthy Infants: A Randomized Clinical Trial</article-title>. <source>JAMA Pediatrics</source> <year>2018</year>; <volume>172</volume>(<issue>7</issue>): <fpage>646</fpage>&#x2013;<lpage>54</lpage>.</mixed-citation></ref>
<ref id="sc39"><label>39.</label><mixed-citation publication-type="journal"><string-name><surname>Shimizu</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Ito</surname> <given-names>Y</given-names></string-name>, <string-name><surname>Yui</surname> <given-names>K</given-names></string-name>, <string-name><surname>Egawa</surname> <given-names>K</given-names></string-name>, <string-name><surname>Orimo</surname> <given-names>H.</given-names></string-name> <article-title>Intake of 25-Hydroxyvitamin D3 Reduces Duration and Severity of Upper Respiratory Tract Infection: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study</article-title>. <source>J Nutr Health Aging</source> <year>2018</year>; <volume>22</volume>(<issue>4</issue>): <fpage>491</fpage>&#x2013;<lpage>500</lpage>.</mixed-citation></ref>
<ref id="sc40"><label>40.</label><mixed-citation publication-type="journal"><string-name><surname>Aloia</surname> <given-names>JF</given-names></string-name>, <string-name><surname>Islam</surname> <given-names>S</given-names></string-name>, <string-name><surname>Mikhail</surname> <given-names>M.</given-names></string-name> <article-title>Vitamin D and Acute Respiratory Infections-The PODA Trial</article-title>. <source>Open Forum Infectious Diseases</source> <year>2019</year>; <volume>6</volume>(<issue>9</issue>): <fpage>ofz228</fpage>.</mixed-citation></ref>
<ref id="sc41"><label>41.</label><mixed-citation publication-type="journal"><string-name><surname>Hauger</surname> <given-names>H</given-names></string-name>, <string-name><surname>Ritz</surname> <given-names>C</given-names></string-name>, <string-name><surname>Mortensen</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>Winter cholecalciferol supplementation at 55&#x00B0;N has little effect on markers of innate immune defense in healthy children aged 4&#x2013;8 years: a secondary analysis from a randomized controlled trial</article-title>. <source>European Journal of Nutrition</source> <year>2019</year>; <volume>58</volume>(<issue>4</issue>): <fpage>1453</fpage>&#x2013;<lpage>62</lpage>.</mixed-citation></ref>
<ref id="sc42"><label>42.</label><mixed-citation publication-type="journal"><string-name><surname>Camargo</surname> <given-names>CA</given-names></string-name>, <string-name><surname>Sluyter</surname> <given-names>J</given-names></string-name>, <string-name><surname>Stewart</surname> <given-names>AW</given-names></string-name>, <etal>et al.</etal> <article-title>Effect of monthly high-dose vitamin D supplementation on acute respiratory infections in older adults: A randomized controlled trial</article-title>. <source>Clin Infect Dis</source> <year>2020</year>; <volume>71</volume>: <fpage>311</fpage>&#x2013;<lpage>7</lpage>.</mixed-citation></ref>
<ref id="sc43"><label>43.</label><mixed-citation publication-type="journal"><string-name><surname>Ganmaa</surname> <given-names>D</given-names></string-name>, <string-name><surname>Uyanga</surname> <given-names>B</given-names></string-name>, <string-name><surname>Zhou</surname> <given-names>X</given-names></string-name>, <etal>et al.</etal> <article-title>Vitamin D Supplements and Prevention of Tuberculosis Infection and Disease</article-title>. <source>N Engl J Med</source> <year>2020</year>; <volume>383</volume>: <fpage>359</fpage>&#x2013;<lpage>68</lpage>.</mixed-citation></ref>
<ref id="sc44"><label>44.</label><mixed-citation publication-type="journal"><string-name><surname>Mandlik</surname> <given-names>R</given-names></string-name>, <string-name><surname>Mughal</surname> <given-names>Z</given-names></string-name>, <string-name><surname>Khadilkar</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <article-title>Occurrence of infections in schoolchildren subsequent to supplementation with vitamin D-calcium or zinc: a randomized, double-blind, placebo-controlled trial</article-title>. <source>Nutr Res Pract</source> <year>2020</year>; <volume>14</volume>(<issue>2</issue>): <fpage>117</fpage>&#x2013;<lpage>26</lpage>.</mixed-citation></ref>
<ref id="sc45"><label>45.</label><mixed-citation publication-type="other"><string-name><surname>Pham</surname> <given-names>H</given-names></string-name>, <string-name><surname>Waterhouse</surname> <given-names>M</given-names></string-name>, <string-name><surname>Baxter</surname> <given-names>C</given-names></string-name>, <etal>et al.</etal> <article-title>The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial: a randomised controlled trial</article-title>. <source>The Lancet Diabetes &#x0026; Endocrinology</source> <year>2020; in press</year>.</mixed-citation></ref>
<ref id="sc46"><label>46.</label><mixed-citation publication-type="journal"><string-name><surname>Rake</surname> <given-names>C</given-names></string-name>, <string-name><surname>Gilham</surname> <given-names>C</given-names></string-name>, <string-name><surname>Bukasa</surname> <given-names>L</given-names></string-name>, <etal>et al.</etal> <article-title>High-dose oral vitamin D supplementation and mortality in people aged 65-84 years: the VIDAL cluster feasibility RCT of open versus double-blind individual randomisation</article-title>. <source>Health Technol Assess</source> <year>2020</year>; <volume>24</volume>(<issue>10</issue>): <fpage>1</fpage>&#x2013;<lpage>54</lpage>.</mixed-citation></ref>
<ref id="sc47"><label>47.</label><mixed-citation publication-type="website"><string-name><surname>Golan-Tripto</surname> <given-names>I.</given-names></string-name> <source>The Effect of Vitamin D Administration to Premature Infants on Vitamin D Status and Respiratory Morbidity (NCT02404623)</source>. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02404623">https://clinicaltrials.gov/ct2/show/NCT02404623</ext-link>.</mixed-citation></ref>
<ref id="sc48"><label>48.</label><mixed-citation publication-type="website"><string-name><surname>Reyes</surname> <given-names>ML</given-names></string-name>, <string-name><surname>Vizcaya</surname> <given-names>C</given-names></string-name>, <string-name><surname>Borzutzky</surname> <given-names>A</given-names></string-name>, <etal>et al.</etal> <source>Study of Vitamin D for the Prevention of Acute Respiratory Infections in Children (NCT02046577)</source>. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02046577">https://clinicaltrials.gov/ct2/show/NCT02046577</ext-link>.</mixed-citation></ref>
</ref-list>
</back>
</article>